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Abstract
Research in immunology has brought great progress in knowledge of
inflammatory processes in the last 2 decades, which also has an impact
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on the upper airways. Our understanding of the pathophysiology of
chronic rhinosinusitis developed from a rather mechanistic point of view
with a focus on narrow clefts and mucociliary clearance to the appreci- 1 Department of
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basis of disease. We today differentiate various forms of inflammation,
we start to understand complex immune-regulatory networks and the
reasons for their failure, and have already developed innovative ap- 2 Division of ENT Diseases,
CLINTEC, Karolinskaproaches for therapy for the most severely ill subjects. Due to this new
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knowledge in inflammation and remodeling processes within mucosal
tissue, specifically on the key driving factors, new diagnostic tools and
therapeutic approaches for chronic rhinosinusitis have developed; the
differentiation of endotypes based on pathophysiological principles will
be crucial for the use of innovative therapies, mostly humanized
monoclonal antibodies. Several hundred of those antibodies are cur-
rently developed for various indications and will impact our specialty
as well as pneumology to a great extent.
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1 Introduction: From
pathophysiology to endotypes of
chronic rhinosinusitis and their
treatment
Chronic rhinosinusitis (CRS) describes a heterogeneous
group of diseases of the nose and the paranasal sinuses
that is characterized by two phenomena: inflammation
and tissue remodeling. According to the European position
paper on rhinosinusitis and nasal polyps [1], CRS is
defined by the presence of at least two of the following
symptoms: nasal obstruction, nasal secretion and/or
post-nasal drip (PND), headaches and/or facial pains, a
reduction of smelling for more than 12 weeks during the
last year while at least one of the first two mentioned
symptoms should be observed. The burden of the symp-
toms, the associated reduction of the quality of life and
the influence of the disease on work productivity are often
underestimated. With reference to the endoscopic find-
ings, the difference is made between the clinical pheno-
types of CRS without and CRS with nasal polyps (CRSsNP,
CRSwNP) [1]. Recent findings on remodeling confirm this
differentiation and reveal that there are significant differ-
ences between the phenotypes. Histologically, CRSsNP
is characterized by fibrosis of the mucosa and the basal
membrane while nasal polyposis is characterized by im-
portant edema with deposition of albumin and the devel-
opment of pseudocysts. The differentiation of the inflam-
mation types based on T helper cells allows amore differ-
entiated classification according to pathomechanical
principles into so-called endotypes within the clinical
phenotypes which can finally be used to define innovative
therapeutic objectives and to implement them in daily
clinical routine.
CRS is one of the most frequently occurring diseases in
humans. Recently, the Global Allergy and AsthmaNetwork
of Excellence GALEN [2] published a first multicenter
prevalence study on chronic rhinosinusitis that is based
on 56,000 questionnaires that were returned by 19
centers in 12 European countries; a random sample was
also submitted to clinical examination by a specialist in
order to confirm the diagnosis [3]. The investigation came
to the conclusion that the prevalence of CRS in Europe
amounts to 10.9%, between 6.9 and 27.1% in different
European cities [4]. Higher prevalences were discovered
in younger people, women, and southern countries;
smoking significantly increased the risk for CRS, depend-
ing on the dose. In the USA the prevalence is even higher
[5]. CRS, however, also affects and increased part of the
older population up to the age of 60, afterwards the incid-
ence decreases. Among all CRS patients in the USA, about
20–33% suffer from CRSwNP, 60–65% suffer from
CRSsNP, and 8–12% from allergic fungal sinusitis (AFS).
One important finding of the GALEN study on chronic
rhinosinusitis was that CRS is associated with an in-
creased risk for a special type of asthma, i.e. a so-called
late-onset asthma or asthma occurring after the age of
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18 [6]. This association was independent from an existing
allergy, in contrast to asthma in early childhood which is
clearly associated with allergic rhinitis. The exact patho-
physiology of this observation is not known up to now.
Mechanisms could consist of the nasobronchial reflex,
aspiration of nasal secretion, inhalation of cold air with
obstructed nose, or the progress of the inflammation
along the airway mucosa. The research program estab-
lished in the USA entitled “Severe Asthma Research Pro-
gram (SARP)” recently identified five different asthma
phenotypes in a cluster analysis; in one of the clusters
with non-atopic late-onset asthma, more than half of the
patients reported about interventions of the paranasal
sinuses [7]. Another investigation of 2,500 asthmatics
revealed that about 51% had rhinosinusitis; CRS was
associated with a deterioration of coughing symptoms
and with a higher number of exacerbations [8]. Those
results confirm the relationship between CRS and asthma;
however, it remains unclear for which type of CRS they
are true and which pathomechanisms are responsible.
Further it is well-known that part of the patients with CRS
will have recurrences even after well performed surgery
and will have to undergo another surgical intervention –
or innovative therapeutic approaches (see the following
chapters) [1]. Own observations show that nearly 80% of
CRSwNP patients develop at least one recurrence over
a time of 12 years after complete surgery of all paranasal
sinuses and removal of all polyps. About 50% of those
patients have to undergo at least one further surgery
(data not published). It would be desirable to understand
the pathomechanisms of this disposition to develop re-
currences and to recognize patients with a high disposi-
tion in the group of CRSwNP patients already at the time
of first surgery [9] in order to be able to adapt treatment
strategies.
It is not possible to fulfill this task only with endoscopes
and CT scans; a basic knowledge of the pathomechan-
isms of inflammation and of remodeling is required as
well as differentiation of CRS into relevant endotypes
based on this knowledge. In the future biomarkers will
be applied for their identification. The understanding of
the pathomechanisms will also define new therapeutic
objectives that will open new possibilities for themanage-
ment of especially severe types of airway diseases. Those
endotypes will allow to give statements on the prognosis
of the disease and their comorbidities and to apply spe-
cific innovative biologics, generally humanizedmonoclonal
antibodies for cytokines or their receptors, in those pa-
tients who have the highest therapeutic potential.
The present paper will first discuss the significant aspects
and regulators of inflammation and remodeling that are
then attributed to the different endotypes on which finally
innovative therapeutic approaches are based. In this
context, very special pathomechanisms and relationships
are explained that play a role in the development of en-
dotypes and that help understanding the diseases and
their secondary consequences. Also the innovative
therapeutic approaches will be understandable and clear.
However, those explanations make no claim to be com-
plete.
2 Selected pathomechanical
principles of the upper airways
The mucosa of the upper airways represents a barrier of
the body between the environment with pollutants,
viruses, and bacteria and the body’s defense system that
can be classified into an unspecific “innate” and a specific
“adaptive” defense. Overlapping of these systems is
profitable. Starting with genetics via the innate and ad-
aptive defenses up to the mechanisms that act against
inflammation in healthy people, deficits were found in
CRS patients that in total cause or at least allow an affec-
tion of the mucosa. In the environment, those defects
have to face invading substances, viruses, and bacteria
that complete and potentiate each other and that, as for
example in the case of Staphylococcus aureus and
Pseudomonas aeruginosa, may establish in the mucosa.
This mechanism leads to a severe inflammatory reaction
that in case of Staph. aureus is further intensified by the
immune proteome of the germ.
2.1 Genetic and epigenetic findings in
chronic rhinosinusitis
Single nucleotide polymorphism (SNP) is a variation of
the DNA sequence where the genome of individuals of a
biologic species is different in the position of one single
nucleotide – A, T, C, or G. Such genetic variations are for
example responsible for predispositions of diseases and
the body’s reaction on environmental stimuli. Up to now,
studies on CRS identified 53 single nucleotide polymorph-
isms (SNP) that are associated with the phenotypes of
CRSwNP or CRSsNP. However, only a pooled genome-
wide association study (pGWAS) was performed [10].
Most association studies (see Table 1) examined only
specific genes of which the products contribute to the
innate immune defense or inflammatory reactions be-
cause findings in those genes are probable in the context
of inflammatory diseases. Unfortunately, many of those
studies including the Canadian pGWAS (173 patients and
130 controls with CRS) were based on patient populations
of relatively small size so that the knowledge on the ge-
netics of CRS is rather limited [10], [11].
Recently we investigated on the reproducibility of all SNP
associations with CRSsNP and CRSwNP described up to
now in a group of Caucasians of European origin [12].
According to the current guidelines, CRS had been dia-
gnosed based on nasal endoscopy and computed tomo-
graphy. The study population consisted of 275 patients
with CRSwNP and 338 patients with CRSsNP as well as
a series of controls from a publicly available database.
This study provided only 7 SNPs that could be reproduced
and that are thus most probably also relevant for our
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patients; however, the existence of further relevant asso-
ciations cannot be excluded.
Table 1: List of SNPs that were associated with CRS in former
publications and that could be replicated in our investigations.
The more those associations are confirmed in other cohort,
the more probable is their significance [12].
ALOX6AB, arachidonate 5-lipoxygenase-activating protein;
DCBLD2, discoidin, CUB and LCCL domain containing 2;
IL22RA1, interleukin 22 receptor, alpha 1; NOS1, nitric oxide
synthase 1; NOS1AP, nitric oxide synthase 1 adaptor protein;
TGFB1, transforming growth factor B1.
Regarding the SNPRs2873551 in the gene of prolyl tRNA
synthetase 2 (PARS2), there was a strong and significant
relationship with CRS; this SNP had already been identi-
fied in the Canadian pGWAS. PARS2 activates amino
acids for protein synthesis by producing aminoacyl-
adenylates. Inhibition of the function of PARS2 causes
suppression of the cellular growth and could have an
impact on the cellular proliferation in combination with
inflammatory processes and the innate immune defense.
The SNP rs1800469 in the gene of TGF-β1 has been as-
sociated with chronic obstructive pulmonary disease and
rhinosinusitis in asthma patients [13]; this cytokine will
be discussed later in the context of remodeling of CRS.
Also SNP rs1483757 in the nitric oxide synthase 1 gene
and the SNP rs4657164 in the nitric oxide synthase 1
adapter protein gene are associated with CRS and are
also found in genes that play a role in asthma and allergic
rhinitis [14]. Nitric oxide also plays an important role in
the pathophysiology of asthma [15] and in the defense
against specific bacteria including Pseudomonas aeru-
ginosa [16].
Comparing CRSwNP and CRSsNP patients, further asso-
ciations could be found. The SNP rs4504543 in the gene
of acyloxyacylhodrolase (AOAH) could lead to a disturbed
degradation of lipopolysaccharides [17]. In the pGWAS,
this SNP had already been related to the CRS phenotype
[10] which was confirmed by a Chinese patient population
[17]. Furthermore, an association with asthma was
identified [18].
So it is obvious that the genetic variations that were found
in our investigation had already been associated with
CRS and partly also with asthma or allergic rhinitis and
thus could play a role in diseases of the airways. The de-
tected associations, however, are independent from the
aspect if patients suffer from asthma or allergic rhinitis.
The SNPs in the gene of PARS2, in the gene of TGF-β1,
and in the NOS1 gene are suitable candidates for further
analyses because also from a biological point of view they
are plausible.
Also in the context of epigenetic processes that signifi-
cantly influence the development and manifestation of
the pattern of the inflammation, tissue specific chronic
inflammatory processes are subject to modifications.
Epigenetic mechanisms are classified into DNA methyla-
tion, histone acetylation, and the formation of non-coding
RNA, so-called miRNA, that influences the expression of
other genes. This is another level of regulation between
genes and proteins that can decisively be modified by
inflammatory processes and also by the environment.
Among others, epigenetic processes lead to functional
modifications in the genomewithout change ormodifica-
tion of the basic DNA nucleotide sequence. Examples of
such modifications are DNA methylation and histone
modifications that both lead to a reduction of the expres-
sion of a gene; however, this may result in an amplifica-
tion or attenuation of the inflammation, depending on
the genes that are expressed in a reduced way. A first
investigation on methylation modifications in CRSwNP
found DNA hypermethylation in 332 loci of 296 genes.
The relevant gene products contributed to lymphocyte
and cellular proliferation, to the activation of leukocytes,
to the biosynthesis and secretion of cytokines, to immune
reactions, to inflammatory processes, and to the immuno-
globulin synthesis [19]. In comparison, hypomethylation
was identified in 158 loci of 141 genes with involvement
in ectodermal development, in hemostasis, in wound
healing, in the binding of calcium ions, and in oxidore-
ductase activity. It is of high significance that within the
arachidonic acid metabolism loci were hypomethylated
in genes responsible for prostaglandin-D-synthase (PDGS),
for 5-lipoxidenase activating protein (ALOX5AP), and for
leukotriene-B4 receptor (LTB4R), while hypermethylation
was found in the gene for prostaglandin-E-synthase
(PGES) [19]. DNA methylation processes can be initiated
by the release of toxic messenger substances because
of the activation of eosinophils [20] that may lead to gene
silencing by expressing hypohalogenous acids; they are
the consequence of eosinophilic diseases, histone hyper-
acetylations can lead to an inhibition of the TGF-β1 in-
duced Smad 2/3, to the restoring of Smad7 signal sup-
pressed by TGF-β1, and to a blockage of the proliferation
of TGF-β1 induced nasal polyp fibroblasts [21], [22].
The genetic transcription is also regulated by non-coding
RNA, e.g. by micro RNA and by long, non-coding miRNA.
An increased expression of miR-125b in the epithelium
of eosinophilic CRSwNP patients in comparison to controls
and non-eosinophilic CRS patients, for example, aims at
4E-BP1, a translation repressor, suppressing type-1 inter-
feron genes [23]. Those genes are needed for the defense
against viral infections. This defense can be disturbed in
those patients (actually a suppression of IFN production
against herpes simplex viruses (HSV) and rhinoviruses in
patients with eosinophilic nasal polyposis is found, in
contrast to control groups, see 2.5.1).
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In an own investigation we assessed the regulation of an
inflammation in two well-defined endotypes, interleuk-
in(IL)-5-positive and IL-5-negative CRSwNP, by miRNAs
in a genome-wide approach by means of miRCURY LNA
microarray platform in mucosal tissue. A total of 86
miRNAs were differentially expressed and could be clas-
sified into 5 different profiles; the investigation indicates
regulatory mechanisms in the mucous production, the
collagen synthesis, the cytochromes P450, and the
glycosphingo-lipid-biosynthesis that is regulated via
miRNAs (Zhou Peng, in press). Hence, there are new
possibilities to examine further pathomechanisms, and
probably therapeutic approaches in the future, because
miRNAs can also be blocked.
2.2 Congenital immune defense:
mechanisms and deficits
The upper airways are covered by amucosal layer consist-
ing of ciliated, pseudo-stratified columnar epithelial cells
(EC) and mucus producing goblet cells. The drainage of
the mucus is achieved by active mucociliary activity, not
by gravitation. The mucosa is covered by mucus where
micro-organisms, dust, and stimulating particles get
caught. Nasal secretion consists of epithelial cells, goblet
cells, epithelial cell proteins, lacrimal fluid, and vascular
transudation. The primary protein parts of this secretion
are mucin glycoproteins with their peptide structure and
the oligosaccharide side chains. Those glycoproteins de-
cisively influence the consistency of the mucus and fur-
thermore they influence the interaction between host and
microorganisms [24]. Mucins bind surface adhesins on
microorganisms and thus inhibit their capacity to colonize
the epithelium.Mucociliary activity transports themucus
from the paranasal sinuses into the nasal cavity and the
pharynx where it is swallowed. The relevance of this pro-
cess for the health of the airways becomes obvious in
the high prevalence of sinusitis in patients with genetic
defects influencing the mucociliary flow, as for example
in cases of cystic fibrosis (chloride transport) or Kartagen-
er syndrome (dyskinesia of the cilia). The nose has a large
mucosal surface with a mucus layer that filters air
particles and tempers and moistens the air flowing over
it. In the nasal submucosa, vascular plexus are found
that swell after exposition to certain triggers such as
stimuli, temperature changes etc.; further more mucus
is produced.
Mucin 5AC andmucin 5B are themost important secreted
mucins and determine the consistency of the mucus
significantly. Both are especially up-regulated in eosino-
philic CRSwNP. Recently we could show that the regula-
tion of both mucins occurs via the Th2 cytokines IL-4 and
IL-13 while IL-5 has no influence [25].
2.2.1 Antimicrobial peptides
Epithelial cells release a wide range of antimicrobial mo-
lecules, as for example enzymes (lysozyme, chitinases,
and peroxidases), opsonins (complement and pentraxin-
3), permeabilizing proteins (defensins, cathelicidins), C1
complexes (surfactant protein A, surfactant protein D,
andmannose-binding lectin), and ligands (lactoferrin and
mucins) [26], [27]. Beside their antimicrobial effect they
have different other effects on cellular differentiation and
wound healing [28]. The protein PLUNC (palate, lung, and
nasal clone protein) is secreted by glandular epithelium
and not by surface epithelium. Probably it is of particular
importance for airway diseases because it has biofilm
inhibiting properties.
A weak host defense could be the result of a primary de-
fect of the innate immunity in the paranasal sinuses, but
it is also possible that it is a consequence of chronic
eosinophilic airway inflammation. There are hints that
Th2 cytokines might down-regulate the production of
mediators of the innate immunity, such as for example
human beta defensing 2 and surfactant protein A [29].
Other cytokines, in particular T cell cytokine IL-22, induce
mediators of the innate immune defense in epithelial
cells by activating STAT3 (transcription factor signal
transducer and activator of transcription 3) which is a
mediator of mucosal host defense and epithelial repair
mechanisms [30], [31]. Th2 polarization may lead to a
reduced expression of IL22 receptor and STAT3 signal
pathway [32], [33].
Also taste receptors (taste receptor family 2 (T2R)), also
called “bitter taste receptors”, that were first described
in the tongue, are expressed in the airways and assess
toxic chemicals but also signal of bacteria they release
for communication among each other. In this way, the
receptor T2R38 is activated by secreted products of
Pseudomonas aeruginosa which leads to the induction
of nitric oxide and finally to bacterial death [34]. Genetic
defects of the receptor increase the risk of infection with
gram-negative germs.
2.2.2 Epithelial barriers
Respiratory epithelial cells are connected via adhesion
complexes, consisting of apical tight junctions, intermedi-
ate junctions, desmosomes, and hemi-desmosomes. A
reduced expression of the tight junction proteins of
claudin and occludin [35] or desmosomal proteins [36]
can play a key role in the etiology of diseases of the upper
airways. Reduced concentrations of protease inhibitors,
such as the serine protease inhibitor Kazal type 5
(LEKT1), in the epithelium may lead to an increased
sensitivity for the activity of endogenous and exogenous
proteases [37]; fungi, bacteria, and many allergens dis-
pose of a significant intrinsic protease activity. A simultan-
eous weakness of endogenous protease inhibitors such
as LEKT1 could have the effect that the mechanical bar-
rier cannot counter a protease attack so that foreign
proteins can pass the mucosal barrier more easily.
In nasal polyps, occludin, the Zonula occludens 1 protein,
and E-cadherin are expressed in a reduced way so that
the epithelial barrier can be passed more easily by viral
and bacterial infections [38], [39] (Figure 1).
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Figure 1: Expression of tight junction molecules in patients with CRSwNP in comparison to healthy people (inferior turbinate):
significantly reduced expression leading to weak epithelial barrier in CRSwNP
2.2.3 Receptors of congenital immune defense:
Toll-like, NOD-like, and RIG-like receptors
Epithelial cells of the nose and the paranasal sinuses do
not only represent a physical barrier, but have active
functions in the context of innate and acquired immune
defense [40]. They express membrane-bound and cyto-
plasmatic pattern recognition receptors (PRR) that recog-
nize pathogen-associated molecular patterns (PAMPs)
[41]. The activation of those receptors leads to the re-
lease of chemokines and cytokines and components of
the innate immune system activating further immune
cells (for example neutrophils). Different microbial factors
or PAMPs, such as for example bacterial lipopolysacchar-
ides (LPS), flagellin, lipoteichoic acid, peptidoglycan,
double stranded RNA, and unmethylized CpG motives,
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can be recognized by many PRRs [42]. The activation of
PRRs in the nasal epitheliummay lead either to the induc-
tion of tolerance or to the expression of inflammatory
mediators attracting neutrophil lymphocytes.
Several groups of such receptors were described recog-
nizing PAMPs, among them toll-like receptors (TLR), nuc-
leotide-binding oligomerisation domain (NOD) like recept-
ors, retinoic acid induced gene (RIG)-1-like receptors, and
the melanoma differentiation associated gene (MDA)-5.
The complex of TLR currently encompasses 10 integral
membrane glycoproteins that recognize extracellular and
intracellular PAMPs [43]. All TLR signaling pathways lead
to activation of the transcription factor NF-κB (nuclear
factor kappa B) which controls the expression of numer-
ous genes for inflammatory cytokines. Obviously, all TLR
are expressed in the healthy nasal mucosa as well as in
cases of CRS [44]; however, the expression of TLR2,
TLR4, and TLR9 receptors and their effector molecule
NF-κB in the mucosa of CRS patients is higher compared
to healthy people [41], [44], [45], [46]. Disturbed expres-
sion of those receptors may contribute to the develop-
ment of CRS [47].
Intracellular PAMPs, such as for example muramyl
dipeptide (MDP) and peptidoglycan are recognized by
NOD-like receptors. NOD-like receptors are expressed in
the epithelial cells of the nose and the paranasal sinuses
[48]. Epithelial cells further express protease-activated
receptors (PAR) [49] that are activated by different endo-
genous and exogenous proteases, including those that
are associated with bacteria, fungi, and allergens [50].
The activation of PAR also induces the NFκβ signaling
pathway [51]. Proteases of Staphylococcus aureus acti-
vate PAR-2 and lead to a release of interleukin (IL)-8 [49],
[52]. In cases of chronic airway diseases, epithelial cells
express more PAR2 than under healthy conditions [49].
2.2.4 Indicators of cellular death:
damage-associated molecular patterns
(DAMPs)
Beside pathogen-associatedmolecular patterns (PAMPs),
cells also recognize cellular damages because of their
damage-associated molecular pattern (DAMPs). The
combination of foreign material plus cellular damages
triggers a reaction of the innate immune system and ac-
tivated the adaptive immune defense or contributes
substantially to its manifestation [53].
In addition to actively secreted inflammatorymessengers,
recently also those messengers are in the focus of sci-
entific attention that are part of the endogenous intracel-
lular or extracellular matrix of the host and can be re-
leased passively into the extracellular space. When re-
leased, the original functions of those components
change so that they modulate inflammatory reactions
under pathologic circumstances in their new environment.
In analogy to the PAMPS, those molecules were named
DAMPs [54], [55], [56].
Intracellular molecules with extracellular DAMP function
are released either passively by damaged cells during an
inflammatory or infectious event or actively by certain cell
types via so-called alternative secretory pathways because
per definition the leader sequence for secretion ismissing
[56]. DAMPs from the extracellular matrix of the host can
be released in cases of damage or by regulated shedding
mechanisms [57]. Currently, more than 40 molecules
have been classified as DAMP. They exert their effect
through activation of at least one toll-like receptor (TLR)
or other members of the PRR family, for example via
“scavenger receptors” (e.g. CD36) or specialized receptors
such as RAGE receptor (receptor for advanced glycation
end products) [57]. Several DAMPs also bind to ECM
structures like heparan sulphate proteoglycans [56], [57]
(Table 2).
Concerning the upper airways, up to now from all known
DAMPs and their respective receptors, only the multi-lig-
and receptor RAGE has been examined intensively [58].
RAGE is a cellular surface protein that is part of the im-
munoglobulin superfamily and that is made responsible
for different inflammatory reactions. RAGE is expressed
in full length as membrane-bound receptor (mRAGE), but
it also appears as two soluble forms without transmem-
branous or cytoplasmatic domain; together they are called
“sRAGE”. sRage originating from alternative mRNA spli-
cing is classified as “endogenous secretory RAGE” or
esRage while RAGE occurring from proteolytic splitting of
mRAGE is called cRAGE; this process is initiated by
metalloproteinases (MMPs) and ADAMs (A Disintegrin
And Metalloproteinases) [59], [60], [61].
mRAGE binds to several ligands, for example to AGE
products (advanced glycation end products), HMGB1
(high mobility group box 1), members of the S100/Cal-
granulin family, the IntegrinMac-1, and to ECM structures
such as heaparan sulphate proteoglycans (HSPGs) [62].
sRAGE, on the other hand, seems of act often as kind of
a bait receptor with inflammation-inhibiting properties by
“intercepting” RAGE ligands of mRAGE surface receptors
that transduces inflammatory reactions via the transcrip-
tion factor NF-κB [63], but it can also promote the inflam-
mation [64]. FormRAGE, too, certain inflammation-inhib-
iting characteristics have been described [65].
Under normal physiological conditions, RAGE is expressed
to a high degree in the lungs – in contrast to many other
tissues [65], [66]. In humans, RAGE is also highly ex-
pressed in the upper airways under normal physiological
conditions and in cases of chronic inflammations it is
subject to differential regulation. In CRSsNP, the sRAGE
protein quantities are increased whereas the quantity of
mRAGE is reduced compared to the control groups. In
CRSwNP, the sRAGE and mRAGE protein quantities are
reduced in the tissue [58] which is due to an imbalance
of metalloproteinases and their natural inhibitors (TIMPs)
[67].
Because of the relative lack of collagen in CRSwNP and
the excessive collage production with thickening of the
collagen fibers in the extracellularmatrix (ECM) in CRSsNP
[21], [67], the fibrotic tissue has higher quantities of
sRAGE than pseudocystic tissue of CRSwNP patients be-
cause sRAGE bind to those structures in the long term
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Table 2: Overview of the expression of damage-associated molecular pattern (DAMPs) and their receptors in CRS and other
diseases of the upper airways
[66], [68]. In CRSwNP patients, the increased colonization
incidence of Staph. aureus may contribute to further re-
duction of sRAGE [69] because Staph. aureus induces
the release of sRAGE from the ECM [58]. The higher
amount of ECM-associated sRAGE in CRSsNP induces an
inflammation that is polarized in direction of Th1 [58].
RAGE participates in the differentiation of T cells to a Th1-
phenotype; if RAGE is missing, the production of Th1 cy-
tokines is reducedwhilemore Th2 cytokines are produced
[70]. Additionally, in CRSwNP a higher amount of protein
is found of eosinophil-cationic protein ECP that degrades
non-ECM-associated sRAGE so that a reorientation of
T helper cells in direction of Th1 is inhibited [58].
Calcium-binding proteins S100A7 (psoriasin), S100A8
(MRP8 or calgranulin A), S100A9 (MRP14 or calgranulin
B) and their heterodimer types of S100A8/A9 (calpro-
tectin) have been examined in CRS patients because of
their antimicrobial effect [28], [37]. S100 proteins have
the typical properties of DAMPs when they are released
into the extracellular milieu where they activate TLR4
[71], [72] and possibly also RAGE [73]. In comparison to
healthy people, the expression of S100A7, S100A8, and
S100A9 mRNA is reduced in patients with CRSsNP and
CRSwNP [74]. S100A7 proteins are reduced in the epi-
thelium and in glandular structures in CRSwNP and also
the nasal lavage fluid of those patients shows low
quantities of S100A7 [37]. In comparison, the amount
of heterodimer S100A8/A9 proteins is extremely in-
creased in the polypous tissue because of the higher in-
filtration of neutrophils, which is a main source of
S100A8/A9 proteins [37]. These results indicate that
secreted S100A7 and S100A8/A9 proteins fromepithelial
and/or glandular tissue play a role as antimicrobial sub-
stance in the paranasal sinuses and allow the hypothesis
that reduced quantities are a possible key to CRS patho-
genesis.
Fibronectin is amacromolecular glycoprotein of the extra-
cellular matrix that is very important in the context of
wound healing, cell adhesion, matrix formation, protein
secretion, cell differentiation, cell cycle progression, and
mitogenous signal transduction [75], [76]. It is also asso-
ciated with immune processes that occur via activation
of TLR4; it then has the effect of DAMP [77]. Fibronectin
is also considered as target molecule of a high number
of bacterial proteins, the bacterial fibronectin binding
proteins (FnBPs) [78]; it mediates the adherence of
Staph. aureus to the extracellular matrix and to the sur-
face of host cells, for example to endothelial cells, epi-
thelial cells, and fibroblasts, through which Staph. aureus
can enter into the cytoplasm of those cells [78], [79]. In-
side the cell, Staph. aureus is protected against antibiot-
ics and the immune reactions of the host [79] and thus
it can survive which in view of the increased fibronectin
expression [39] and the high colonization rate with
Staph. aureus explains the intramucosal presence of
bacteria especially in CRSwNP patients [69].
2.2.5 Lymphoid cells of innate immune defense
(ILCs, innate lymphoid cells)
Epithelial cells in the airways produce numerous inflam-
matory cytokines as normal reaction of the stimulation
of PAMP and DAMP receptors [51], among those IL-1,
tumor necrosis factor α (TNF-α), type 1 interferons
(IFN-α/β), granulocyte macrophage colony stimulating
factor (GM-CSF), eotaxins, RANTES (regulated upon activ-
ation normal T-cell expressed and secreted), IFN-γ-indu-
cible protein 10 (IP-10), IL-6, IL-8, the growth-regulated
oncogene α (GRO-α), monodansylcadaverine (MDC), stem
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cell factor (SCF), TARC (thymus and activation regulated
chemokine), monocyte chemotaxis protein 4 (MCP-4),
B cell activating factor (BAFF), osteopontin, IL-32, and
Th2 immune reaction associated cytokines such as IL-25,
IL-33, and TSLP (thymic stromal lymphopoietin) [26], [49].
Those cytokines do not only cause tissue swelling, vascu-
lar dilation, and other characteristics of inflammations,
but they often have also chemotactic properties, by which
they attract different leukocytes, mast cells, neutrophils,
dendritic cells, and lymphocytes to the locus of the inflam-
mation. Also cytokines produced by epithelial cells play
a major role in the polarization of dendritic cells and thus
influence the type of T cell reaction on antigens [80].
Apparently, there are very special epithelial cell cytokines
(IL-25, IL-33, and TSLP) that induce the polarization of
dendritic cells and the subsequent T cell differentiation
on mucosal antigens [80]. Those cytokines have the
particular ability to influence the differentiation of T-cells
in direction of Th2-profile as it is known from CRSwNP.
Presumably, epithelial cells do not only contribute signi-
ficantly to the mediation of reactions of the innate im-
mune defense but also influence in this way the sub-
sequent adaptive immune defense. Currently it cannot
be excluded that the etiology and pathogenesis of CRS
are based on primary variations of the reaction pattern
of epithelial cells.
Lymphoid cells of the innate immune defense (innate
lymphoid cells, ILCs) have important effector and regula-
tion functions in the innate immune defense and remod-
eling of tissue, however, they do not perform receptor
rearrangement (this property is termed “lineage nega-
tive”). ILCs are classified into three categories based on
the characteristic patterns of the cytokines they produce
and the transcription factors that are necessary for their
development and function analogous to the T helper cells:
Group 1 ILCs (ILC1) produce interferon γ and depend
from the transcription factor Tbet, while group 2 ILCs
(ILC2) can produce Th2 cytokines such as IL-5 and IL-13
and therefore need the transcription factor GATA3. Group
3 ILCs (ILC3) also comprise lymphatic tissue inducing
cells. ILC3s can produce IL-17 and/or IL-22 and require
RORγt as transcription factor. In this regard, ILCs are very
similar to T helper cells, however, they are part of the in-
nate immune defense and according to the current
knowledge they form the link between epithelium and
T cell compartment [81].
CRTH2 and ST2 (IL-33 receptor)-positive ILC2s have been
detected in healthy human lungs; however, it is currently
unclear which functions ILC2s have in humans in com-
parison to Th2 effector cells (that both produce IL-5
and IL-13) in the context of pulmonary hemostasis. Ac-
cordingly, CRTH2+ILC2s have been identified in CRSwNP
tissue [82]. TSLP – an ILC2-activator produced by epitheli-
al cells – is expressed to a high degree in epithelial cells
of CRSwNP tissue in patient with asthma [83]. Only little
is known about the function of other ILC subgroups in the
airways.
In contrast, lipoxin A4, a lipidmediator with inflammation-
resolving properties, via the inhibition of IL-13 production
of ILC2s [84]. LXA4 also causes the number of eosinophils
to decrease by favouring the NK cell mediated apoptosis
of those cells. ILC2 localizes in the airways near themast
cells that release prostaglandin D2 (PGD2) which in-
creases the IL-13 production of ILC2s via the PGD2 re-
ceptor CRTH2. Thus the activity of ILC2s is regulated by
the balance between LXA4 on the one hand and PGD2
on the other hand, whereas both LXA4 and PGD2 are in-
creased in CRSwNP. However, this balance is again dis-
turbed in cases of aspirin sensitivity [85], [86].
2.2.6 Dendritic cells and macrophages
Dendritic cells (DCs) are the link between innate and ad-
aptive immune defense on mucosa. In the airways, sev-
eral functional subgroups of DCs have been described
that differ with regard to their stage of maturity and the
expressed combination of PRRs [87]. DCs recognize anti-
gens and process and present them to antigen unversed
or “naïve” T cells. Because of these functions, DCs play
a key role in the fine adjustment of immune reactions
and favor the production of Th1, Th2, or Th17 reactions
or regulatory T cells (Tregs) [80]. In the nasal mu-
cosa, 4 different DC subgroups could be identified: 2
myeloid DC populations (mDC) that express either BDCA1
(Blood Dendritic Cell Antigen 1) or BDCA2, a plasmacytoid
population of dendritic cells (pDC) that is BDCA1 and
CD123 positive (CD = cluster of differentiation), and BD-
CA1 and CD207 positive Langerhans cells [88]. In
CRSwNP tissue where the inflammation pattern is polar-
ized in direction of Th2, an increased number of mDCs
and pDCs could be found [89]. This distribution pattern
of DCs could contribute to the persisting airway inflamma-
tion in cases of CRSwNP.
Macrophages are cells of the innate immune defense
that have various functions, as for example to remove
particles, to primarily react on pathogens, to maintain
tissue hemostasis, to coordinate the adaptive immune
defense, to develop inflammation and tissue repair [90].
In accordance to the factor macrophages come in contact
with, they polarize to a classically activated inflammatory
M1 phenotype or to an alternatively activated M2 pheno-
type [91]. M1 macrophages express inflammatory cy-
tokines to a high degree such as IL-1β, IL-12, IL-23, and
TNF as well as effector molecules as nitric oxide. They
contribute to the induction of Th1 reaction and inhibit the
survival of pathogens by destroying themeffectively inside
the cells [92]. However, we could observe that macro-
phages in IL-5 expressing CRSwNP tissue were mainly
M2 polarized and had a high expression of CD206 [93].
Remarkably, M2 macrophages were not able to perform
phagocytosis nor to destroy germs like Staph. aureus,
and this circumstance promotes the intracellular survival
of those germs (see later). Furthermore,M2macrophages
from nasal polyps release high quantities of the
chemokine ligand 18 (CCL18) which has a chemotactic
effect on DCs, naïve T cells, and Th2 cells; all those cells
contribute to the pathogenesis of CRSwNP [94] (Figure 2).
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Figure 2: Macrophage subtypes in healthy control mucosa and tissue of eosinophilic nasal polyps: increase of M2macrophages
having significantly limited phagocytosis activity
2.3 Adaptive immune defense: T cells
as central components
The adaptive immune defense consists on the one hand
of T cells that are especially targeted for this challenge.
They may be subdivided into several groups according to
the released cytokines and their functions. On the other
hand there is the B cell response that is targeted to the
production of specific antibodies. The resulting T cell re-
sponse should be subject to the regulation of T regulatory
cells; if not, persisting inflammation occurs. Other
bystander cells such as eosinophils andmast cells further
modify and amplify the inflammation process, in particular
in cases of Th2 reaction. Such cell components sum up
the processes that finally lead to most severe diseases
of the mucosa, mainly Th2 characterized.
2.3.1 T helper cell patterns
While CRSsNP appears as an only moderate, mainly
neutrophil Th1 polarized inflammation, CRSwNP is char-
acterized beside the neutrophil component by amoderate
to high eosinopilic Th2 polarized inflammation, at least
in Caucasians [95]. Presumably, the reduced TGF-β ex-
pression in the CRSwNP tissue contributes to a deficit of
Tregs [13], [21], [96] like the strong expression of sup-
pressor of cytokine signaling 3 (SOCS3) which is further
enhanced by the reduced migration of regulatory T cells.
SOCS3 and Foxp3, which is an important transcription
factor of T regulatory cells, is co-expressed in Tregs;
SOCS3 regulated Foxp3 expression probably via phos-
phorylation of STAT3 [96]. The relative deficit of Tregs
could be the reason for the inability to suppress the eos-
inophilic inflammation in CRSwNPpatients. In Caucasians,
more than 80% of the polyps express a Th2 profile with
clear expression of interleukin-5 protein and consecutive
tissue eosinophilia whereas this profile is found in less
than 20% of all central Chinese CRSwNP patients. In-
stead, there are Th17 cells that induce a mainly neutro-
phil inflammation reaction [97].
An extensive flow cytometry of the T cell subtypes was
performed in the affected and healthy nasal mucosa in
CRS patients [98]. Most of the T cells in the nasal mucosa
were CD45RA negative and had an effector phenotype,
whereas T cells in the bloodmostly havemarkers of naïve
T cell phenotypes. Both in the healthy and in the affected
nasal mucosa, a heterogeneous population of T helper
cells was present: Th1, Th17, Th22, and Tfh (follicular
helper) cells were found. A certain plasticity of the
T helper cells could be revealed because for example the
Th17 cell population produced not only IL-17, but also
IFN and IL-22. The reason for this heterogeneity among
the effector T cells might be associated with their protect-
or function, i.e. according to the type of the entering mi-
croorganisms, several optimal immune reactions should
be possible. The results show that the T cell profile of
CRSsNP specimens only differs little from the control
specimenswhich confirms previous findings that CRSsNP
is rather a remodeling process than a specific inflammat-
ory reaction [21]. It was remarkable that Th2 cells could
only be identified in CRSwNP specimens while asthma
patients had the highest number of cells. This pattern
correlates with protein data of homogenized tissue speci-
mens after multiplex cytokine analyses [99]. Even if IFN
gamma is themost important intracytoplasmatic cytokine
in T cells, as protein only low concentrations can be de-
tected in tissue homogenates; apparently IFN is not
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Figure 3: T cell pattern after stimulation and inhibition of the release of cytokines by Brefeldin. Only in cases of nasal polyposis,
the T helper cell 2 faction is obvious (IL-4 and IL-5 producing T cells).
spontaneously released under basic conditions whereas
high concentrations were found after stimulation in the
cell free supernatant. IL-5, however, is only expressed by
relatively few CD4 positive T cells, but regularly released
spontaneously by a CRSwNP endotype; this spontaneous
release can be significantly increased by intramucosal
Staph. aureus germs (see later).
Beside CD4 positive T cells, there is a larger population
of T cells in the nasal mucosa that belong to the CD8 cell
line and that are the main source of IFN gamma. CD8
positive cytotoxic T cells (Tc cells) express high quantities
of Fas ligand that may induce apoptosis in other cells.
Another important function of IFN producing CD8 positive
T cells (so-called Tc1 cells) is their ability to inhibit IgE
response.
The presence of Th2 cells and the expression of IL-5 is
associated with eosinophilia, an increased ECP (eosino-
phil cationic protein) and the total amount of IgE in the
mucosa, independent of the atopic status of the patients
[97]. The percentage of IL-5 positive nasal polys in Europe
amounts to about 85% of all CRSwNP while the percent-
age in Central Asia, for example in China, is significantly
lower with 15% [97]. IL-5 is important for the survival and
activation of eosinophils and can be produced by lymph-
ocytes, mast cells, and the eosinophils themselves [100].
The important role of IL-5 for the survival of eosinophils
in nasal polyps was revealed in ex vivo trials with human
nasal mucosa with neutralizingmonoclonal anti-IL-5 anti-
bodies that induced apoptosis in eosinophils and signific-
antly reduced the synthesis of IL-5 and thus also the
number of eosinophils. Based on this observation, we
performed a pilot projects and studied the possibility to
treat severe nasal polyposis with a humanizedmonoclonal
antibody against IL-5 (Mepolizumab) [101]. Two single
intravenous injections of 750 mg Mepolizumab led to a
significantly improved nasal polyp score in comparison
to a placebo group and to a reduction of the polypous
mass revealed in computed tomography. This proof-of-
concept study confirms the role of IL-5 in CRSwNP and
proves the significance of biomarkers for the prognosis
and thus the optimized patient selection (Figure 3).
2.3.2 B cells and local immunoglobulin
production
In CRSwNP, the total number of B and plasma cells such
as the relation of plasma cells and B cells is partly much
increased in comparison to control groups which might
be a hint to an active B cell compartment in this disease,
but not in CRSsNP [102]. In cases of eosinophilic
CRSwNP, the local IgG and IgE concentrations, and im-
portant markers of a local immunoglobulin class switch
are as well increased in comparison to allergic rhinitis
and healthy people [103]; also this phenomenon is not
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observed in CRSsNP. During the immunoglobulin class
switch, recombination events occur (class switch recom-
bination, CSR) typically via IgG4 to IgE. In up to 30% of
the B cells, plasma cells, and T cells in nasal polyps a
repeated expression of RAG1 and RAG2 (recombination
activation genes) can be revealed that are necessary for
receptor revision [103]. Furthermore we were able to
identify the up-regulation of activation-induced cytidine
deaminase (AID), which is a factor indicating as well an
active CSR and somatic hypermutation of immuno-
globulins [104]. In CRSwNP, the concentrations of RAG1
and RAG2 mRNA is increased and correlates with the
severity of the inflammation and the presence of Staph.
aureus enterotoxin (superantigen)-specific IgE in the
mucosa of nasal polyps. Those results prove a local re-
ceptor revision and the class switch to IgE and the differ-
entiation of B cells to IgE secreting plasma cells in poly-
pous tissue of CRSwNP without obligatory involvement
of other lymphoid structures as for example lymph nodes.
In tissue homogenates of CRSwNP the concentrations of
important markers of Th2 induced inflammatory pro-
cesses including IL-4 are significantly increased; IL-4
stimulated the synthesis of the ε-germ line transcript
(GLT) that is used during CSR to IgE [103]. In CRSwNP,
the concentrations of ε-GLT are significantly increased.
The same is true for the B cell activating factor of the TNF
family (BAFF) [105], which stimulates the development
of follicles, and the B lymphocyte-induced maturation
protein (BLIMP). Both BAFF and BLIMP are involved in
the differentiation of B cells to plasma cells [106], [107].
Finally, we could reveal the presence of Iε-Cc class switch
transcripts bymeans of gel electrophoresis and southern
blotting and confirm it by sequencing of 339 bp long cDNA
sequence, which unequivocally proves the local class
switch in CRSwNP tissue [103]; a local IgE synthesis was
previously shown in allergic rhinitis [108].
The proof for the local receptor revision was given by the
up-regulation of RAG1 and RAG2 in B cells, plasma cells,
and T cells. Indeed, the percentage of those cells that
express RAG proteins in CRSwNP is similar to tonsillar B
cells (15–26%) and significantly higher than in circulating
B cells (<5%). Relevantly high percentages of B cells
(20–30%) can also be found in target organs of autoim-
mune diseases. Recently it could be shown that both
BAFF and the autoantibody are increased in nasal polyps
and possibly play a role in the pathogenesis of CRSwNP
[109].
Staph. aureus enterotoxin IgE was found in about 30%
of CRSwNP patients, but not in the nasal mucosa of
control groups. In the SE IgE positive polyps, the quantities
of IgE, ECP, but also RAG1 and RAG2 were significantly
increased than in SE IgE negative polyps which may be
a hint to a direct stimulation of the RAGs by
Staph. aureus. The correlation between RAG expression
and a confirmed contact with Staph. aureus enterotoxins
proves convincingly that reactions have been stimulated
in the local germinal center and the polyclonal IgE expres-
sion by superallergenes [103]. We have already shown
that local SE specific IgE directed against enterotoxins
and polyclonal IgE resulting from the activation of plasma
cellsmay contribute to the form and persistence of inflam-
mation in CRSwNP; such IgE antibodies are active against
several 100–1,000 different inhalative allergens and
against allergens of Staph. aureus itself and cause a de-
granulation of mast cells after exposition [110]. Those
results correspond to the fact that the treatment of
CRSwNP with anti-IgE antibodies (Omalizumab) clearly
reduces the size of the polyps and the symptoms of the
disease (Figure 4, Table 3).
2.3.3 Mast cells and eosinophilic granulocytes
Mast cells often occur in the nasal mucosa and have a
physiologic function in the context of innate immune de-
fense and wound healing. The activation of mast cells
leads to the release of already present granules contain-
ing histamine, serotonin, proteoglycans, and serine pro-
teases and to the de novo synthesis and release of differ-
ent eicosanoids, chemokines, and cytokines. Prostagland-
in D2 from mast cells was correlated with the recruiting
and activation of Th2 lymphocytes in nasal polyps [86].
The stem cell factor (SCF) released from epithelial cells
might substantially contribute to the recruiting of mast
cells in nasal polyps [111]. In cases of allergies, themast
cell degranulation is initiated via an antigen-induced
linkage of IgE molecules that are bound to highly affine
receptors on the mast cell surface. However, there are
other IgE-dependent and IgE-independent processes in-
ducing, enhancing, andmaintaining degranulation [112].
In particular, studies with explanted polyps have shown
that a mast cell degranulation can also be triggered by
other mechanisms including protein A (SpA), which is a
surface protein of Staphylococcus [113]. Interestingly, it
could not be definitely clarified if the number of mast
cells in CRSwNPwas increased in comparison to CRSsNP
or control tissue [114]. Functional studies, however, allow
the hypothesis that mast cells are much more active in
nasal polyps and in vivo reactmore sensitively on external
triggers [113]. With regard to the massive polyclonal IgE
production, which is typical for CRSwNP, and to the pos-
sibility of direct activation of mast cells by means of spe-
cial proteins of Staph. aureus, it is highly probable that
in cases of CRSwNP a persisting activation of mast cells
occurs. The inhibition of the continuous mast cell activa-
tion by innovative approaches might contribute to clarify-
ing the significance of those cells in persisting inflammat-
ory processes.
Eosinophils are circulating granulocytes that are respon-
sible for immune defense at mucosal surfaces, primarily
againstmulticellular parasites, but also for the remodeling
and the repair of the mucosa. Their high amount in the
mucosa of the airways in CRSwNP is associated by some
authors with a certain origin of a disease, especially with
the infection with fungal spores, however, there is still no
final proof. The degree of eosinophilia in CRS is independ-
ent from the simultaneous presence of allergic rhinitis or
fungal sinusitis which possibly allows concluding overlap-
ping pathophysiological processes. In addition, the degree
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Table 3: Polyclonal IgE in the tissue of CRSwNP [209]: High total IgE concentrations and numerous IgE specificities characterize
the local IgE in nasal polyps. Specific IgE against: gx1 grass pollen mix, hx2 house dust mites mix; mx2 fungal allergen mix; tx9
tree pollen mix; superantigens SEA – TSST
Figure 4: IgE positive B cells and IgE producing plasma cells in nasal polyposis
of tissue eosinophilia in CRSwNP correlates with the
severity of the disease, the diagnosis of aspirin sensitivity,
the occurrence of comorbid asthma [115], and the neces-
sity of surgical revision [116]. At the same time, eosino-
philia is not imperatively associated with CRSwNP; in 85%
of the polyps of Asian patients as well as in about 15%
of the polyps of Caucasian patients, the cellular pattern
is not eosinophilic, but neutrophil. Instead of the expres-
sion of IL-5, IL-17 and IFN-γ are found as well as corres-
ponding transcription factors [97].
For eosinophils, the chemokines RANTES, eotaxin 1-3,
MCP 1-4 are relevant that are all mainly secreted by
nasal epithelial cells and exercise their functions via the
receptor CCr3 [117], [118], [119]. Also dendritic cells
and macrophages may contribute to the production of
eotaxin and other CCR3 ligands. The Th2 cytokines IL-4
and IL-13 play an important role in the induction of
chemokines via STAT6 and NF-κβ. GM-CSF and IL-5 in-
duce an enhancedmigration and adhesion of eosinophils
in the tissue of nasal polyps and favor the survival of
those cells; IL-5 is an important priming and survival
factor for eosinophils and antibodies against IL-5 induce
the apoptosis of eosinophils in CRSwNP tissue [100],
[120]. In summary, the process of recruiting, activation,
and differentiation of eosinophils in CRSwNP is mainly
promoted by Th2 cells and the cytokines released by
them. There are sound hints that Staphylococcus super-
antigens favor eosinophilia in polypous tissue by enhan-
cing the local release of Th2 cytokines by acting on the
Th2 cells [99], [113], [115]. Recently, there were even
hints that also Staphylococcus biofilms might favor eos-
inophilia in CRS independent from the polypous status
or from super antigens [121]. The mechanism of this
possible effect is unclear. Factors as for example IL-33,
TSLP, and IL-25, which activate ILC2, might induce the
production of IL-5 and thus influence the immune reaction
in direction of a Th2 profile (Len Feng, unpublished data).
In the literature it is abundantly described that glucocor-
ticosteroids can inhibit the recruiting, survival, and acti-
vation of eosinophils in CRS [122]. A recently performed
double-blind trial with oral corticosteroids confirmed the
clinical, however short-term, effectiveness on the nasal
polyp score and the reduction of IL-5 and ECP in nasal
secretion [123]. Both IL-5 and its soluble receptor are
increased in eosinophilic nasal polyps [124]; this constel-
lation locates the cells in the tissue. Studies with mono-
clonal antibodies against IL-5 showed a clear clinical ef-
fect while the amount of eosinophils in the blood and the
mucosa significantly decreased after this kind of therapy
[101].
Also neutrophils are circulating immune effector cells
with well described functions in the early phase of de-
fense, phagocytosis, and killing of extracellular microor-
ganisms. In CRS, especially the chemokine IL-8 that is
partly released from nasal epithelial cells as reaction on
PAR-2 stimulation seems to trigger the recruiting of
neutrophils [49]. The role of neutrophils in CRS is still
unclear; in the mucosa of mucoviscidose patients, their
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amount is extremely increased together with the concen-
tration of IL-17 [125].
In CRSsNP and CRSwNP, the degree of infiltration with
neutrophils can be compared, in cases of cystic fibrosis
it is much higher; in contrast, the infiltration with eosino-
phils is significantly higher in CRSwNP than in CRSsNP;
each eosinophilic polyp also has a relevant number of
neutrophils. Polyps of Chinese patients were non-eosino-
philic or neutrophil in 85% of the cases [97]. However,
this pattern may change so that the inflammation
achieves a rather eosinophilic character in the course of
time, accompanied by the presence of eosinophilicmedi-
ators, IgE and Staph. aureus in the mucosa [126].
2.3.4 Factors contributing to the resolution of
inflammations (resolvins)
Not only inflammatory processes, but also their resolution
are active processes where numerous lipidmediators are
involved. The recently discovered inflammation resolving
resolvines of the E and D series, protectins, andmaresins
have a strongly inhibiting effect on human cells. This is
why those threemediator families and their acetylsalicylic
acid triggered forms were called specialized pro-resolving
factors (SPMs) [127]. Arachidonic acid (AA) and omega-
3 fatty acid – the essential eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) – are substrates for the
biosynthesis of highly inflammation inhibiting or inflam-
mation resolvingmediator substances. As it is a relatively
young field of research requiring highly sophisticated
measuring techniques, there is only little known about
the presence and role of those SPMs in the upper airways.
However, the pro-resolving mediator substance of lipoxin
A4 originating from arachidonic acid has already been
measured in patients with CRs [85]. Tissue of nasal polyps
from the upper airways of CRSsNP and CRSwNP patients
had higher concentrations of LXA4 than healthy nasal
mucosa; in contrast, the LXA4 concentration in patients
with aspirin sensitivity was relatively reduced in compari-
son to patients with nasal polyposis without such a
sensitivity. Probably, the same pattern could be found in
other SPMs: in order to reduce inflammation, the up-
regulation of pro-resolving factors in the affectedmucosa
is induced; this process, however, seems to be disturbed
in particularly severe types of inflammation such as NERD
so that the inflammation may become persistent. The
external substitution of pro-resolvins might be a possible
therapeutic approach.
2.4 Remodeling of the mucosa of the
paranasal sinuses
Cellular remodeling processes are dynamic processes
where the production and degradation of the extracellular
matrix (ECM) are balanced and regulated by different
mediators among them TGF-β. TGF-β is considered as
central factor in the remodeling process in the airways
because it attracts fibroblasts, induces their proliferation
and up-regulates ECM synthesis (e.g. of collagen). As
already described, the protein concentrations of TGF-β1
and 2, the expression of mRNA of the TGF-β receptor (R)
I and RIII and the number of activated cells with positivity
for pSmad 2 (phosphorylated protein “mothers against
decapentaplegic homolog”) (which is a sign for the activ-
ation of the cell by TGF-β) is significantly higher in patients
with CRSsNP compared to control groups [21]. In CRSwNP
patients the TGF-β1 protein concentration, the expression
of TGF-β-RII and -RIII mRNA as well as the number of ac-
tivated pSmad 2 positive cells were significantly lower
than in control groups. Those data confirm a relevant
difference between these two CRS subgroups with regard
to the regulation of TGF-β and its signaling which mani-
fests as a deficient collagen production in CRSwNP and
as exceeding collage deposition in the ECM in CRSsNP.
The TGF-β signaling also contributes to the regulation of
metalloproteinases (MMP) and their natural tissue inhib-
itors (TIMP; tissue inhibitors of metalloproteinases). The
overexpression of MMP7 and MMP9 without compensa-
tion by TIMP1 and TIMP4 is associated with a degradation
of ECM, the development of vacuoles, and the deposit of
albumin in nasal polyps, whereas the up-regulation of
TIMP in CRSsNP inhibits edema [67]. Thus, CRSsNPmay
be characterized as fibrosis while CRSwNP is rather de-
scribed as edema.
It might be presumed that the tissue remodeling is a
consequence of the inflammation; this sequence could
be brought in line with the high activation of TGF in the
mucosa adjacent to the polyps and with the deposition
of albumin in nasal polyps correlating with IL-5 [39]. More
recent data, however, allow drawing the conclusion that
remodeling precedes the inflammation at least in CRSsNP
[128]. In a study where TGF-β and inflammatory cytokines
were measured in the different paranasal sinuses of pa-
tients in an early stage of CRSsNP the protein concentra-
tions of TGF-β1 were significantly up-regulated in the area
of the osteomeatal complex, which is the central access
to the paranasal sinuses, and were accompanied by an
increased production and deposition of collagen in this
area. Th1-regulated and inflammatory cytokines or myel-
operoxidase protein as markers of activated neutrophils,
however, were not up-regulated in these patients at that
time. Those observations emphasize the central role of
TGF-β and suggest that the remodeling in CRSsNP occurs
independently from the inflammatory processes and
precedes it (Figure 5 and Figure 6).
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Figure 5: Collagen deposition in the area of the osteomeatal complex in comparison to the inferior turbinate in beginning CRS
Figure 6: Collagen content and collagen bundles in polarized light in control groups, CRSsNP, and CRSwNP. In contrast to the
overproduction of collagen and fibrosis in CRSsNP, there is a deficit of collagen in CRSwNP.
2.5 Interaction between bacteria
(microbiome) and immune defense
According to the current opinion, the detection of patho-
genic germs on the nasal mucosa by swab means auto-
matically disease of at least colonization that may lead
to disease at any time. Frequently occurring germs of
bacterial infections of the upper airways are germs like
Staph. aureus, Hemophilus influenza, Pseudomonas
aeruginosa, and Moraxella catharralis. Today it is well-
known that the nasal mucosa is always, at any time in
life, colonized with hundreds of different germs that – as
far as their presence is balanced – guarantee a healthy
condition. With the advent of the field of molecular bio-
logy, culture independent methods have been developed
in order to examinemicroorganisms based on their genet-
ic patterns. As a consequence, a clearly more complex
flora was discovered in the upper airways than it had
been suspected until that time. Due to the development
of culture independent means it is meanwhile possible
to identify species of microorganisms that could not be
detected with previous growthmethods. Today it is known
that the human body is the home of 10–100 billions of
microorganisms, an amount that is far higher than the
number of body cells. The bacterial flora that has been
known only for a short time is called human microbiome.
Different regions of the body such as the nasal mucosa,
skin, urogenital tract etc. have their own microbiomes
encompassing ideally many microorganisms in relatively
similar low frequencies (“richness, evenness”). If single
germs disturb this balance by proliferation and by sup-
pression of others, a pathologic situation occurs.
Based on the creation of comparingmicriobiome profiles
in a small cohort of CRS patients, on whom no further
details were defined, and healthy test persons, it was
assumed that the flora of the paranasal sinuses of CRS
patients has a significantly lower multitude of bacteria
compared to healthy controls. While on the one hand
numerous phylogenetic distinct lactic acid bacteria were
missing, on the other hand an increase of the relative
incidence of a certain type of Corynebacterium tubercu-
lostearicum was observed [129]. The authors drew the
conclusion that this germ could be made responsible for
the pathogenesis of CRS; for confirmation of its pathogen-
ic role of a certain microbiome constellation in a specific
inflammation status, however, multicentric studies in
large, well defined CRS populations are required [130].
Additionally, the relationship between microbiome and
immune defense in the mucosa could be bidirectional,
i.e. the bacteria exercise a certain pressure while on the
side of the host an insufficient defense is present, for
example because of alternatively activatedmacrophages,
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that show a reduced phagocytosis and an insufficient
killing of intracellular germs [93]. Scientific examinations
on how certain germs influence the immune reaction of
the mucosa of the nose and paranasal sinuses, could
shed new light on the pathophysiology of CRS and lead
to new treatment approaches. The manipulation of the
flora or the introduction of specific healthy germs (e.g.
lactic acid bacteria) might turn out to be helpful for the
treatment of inflammatory diseases and break the dom-
inance of certain germs such as for example
Staph. aureus or Pseudomonas aeruginosa.
2.5.1 Interaction between viruses and bacteria
Common colds rank among themost frequently occurring
infectious diseases of humans and are mainly caused by
human rhinoviruses, the respiratory syncytial virus (RSV)
as well as corona, adeno, and parainfluenza viruses. An
adult suffers about 2–5 times per year under colds while
the rates of infections in females aged between 20 and
34 years are higher, probably because of infection by
their children. Children have 6–8 common colds per year,
day care institutions for children represent a relevant risk
factor for diseases of the airways in children and their
mothers. Because of the fact that certain viruses appear
seasonally, a clear dependence from the seasons is ob-
served with higher incidences in fall and winter [131].
Typical initial symptom of a common cold is a sore throat
because the virus preferably binds via the intercellular
adhesion molecule 1 (ICAM-1) to the tissue of the
nasopharynx/lymph, subsequent nasal symptoms are
sneezing, nasal secretion of fluid or mucus (rhinorrhea),
and nasal obstruction. The infection can extend via the
Eustachian tube to the middle ear or via the trachea into
the lower airways so that coughing and bronchitis occur.
After 10–14 days the symptoms regress spontaneously
if no acute postviral rhinosinusitis occurs [1].
Viral infections of the nasal cavity are the most common
reason of acute asthma exacerbation in children (80–85%
of asthma exacerbations) [132] and in adults (about 80%
of asthma exacerbations) [133]. In two third of the cases
with proven virus, rhinoviruses are detected. In asthmat-
ics, the up-regulation of ICAM-1 on epithelial cells, a re-
ceptor that is used by 90% of the rhinoviruses, might be
responsible for the higher sensitivity especially of atopic
patients with more frequent infections and more severe
and longer lasting symptoms [134]. In vitro studies reveal
that rhinoviruses replicate more efficiently in primary
bronchial epithelial cells of asthmatics than healthy
people. There is a strong correlation between the virus
charge and the severity of the symptoms in the lower
airways and an increase of the bronchial hyperactivity. In
association to the pathogenesis or rhinovirus induced
asthma exacerbations, impaired Th1 reactions (IFN-γ and
IL-12), that seem to have mainly a protective effect
against the replication of viruses, and enhanced Th2 re-
actions (IL-4, IL-5, and IL-13) are described as origin of
more relevant virus-induced asthma symptoms [135].
In adults suffering from mild/moderately severe atopic
asthma and in bronchial epithelial cells of children with
severe therapy-refractory atopic asthma, a defective in-
duction of type-1 interferon (IFN-β) and type-III interferon
(IFN-λ) was found [136]. Actually, patients with severe
therapy-refractory asthma had an increased virus replica-
tion that correlated negatively with the amount of inter-
feron mRNA. Also a study performed with asthmatic chil-
dren living in cities revealed that the treatment with anti-
bodies against immunoglobulin E (IgE) could improve the
control of asthma, reduce the need of asthma medica-
tions, and nearly eliminate the seasonal peaks of exacer-
bations induced by virus infections [137]. This would
mean that the reduced Th1 immune reactions might be
based at least partly on an enhanced Th2 immune re-
sponse.
Actually, unpublished results show that also tissue of
nasal polyps in the ex vivo mucosal model respond insuf-
ficiently to herpes simplex virus (HSV1) and rhino virus
infections; a deficient IFN-γ production and IL-17 release
as well as an increased release of TNF-α were the main
characteristics of mucosal reaction on a virus infection
in CRSwNPwith Th2 polarization in comparison to healthy
inferior turbinates (Lan Feng, in press). This deficient
virus defense could lead to another phenomenon: as
virus infections open the doors to bacteria and allow them
entering into the mucosa despite an otherwise intact
epithelial barrier [138], the probability of bacterial ingress,
such as for example Staph. aureus, could be increased
in cases of frequent virus infections. Because of the fact
that an alternative activation of macrophages occurs in
a Th2 polarized environment (IL-5 plus CRSwNP), the in-
truders could avoid the defense mechanisms of the mu-
cosa in such a situation and colonize themucosa without
being phagocytized or killed by macrophages [93]
(Figure 7).
2.5.2 The role of Staphylococcus aureus as
amplificator of the inflammation
Staph. aureus colonizes the nose very frequently; about
one third of all Europeans are life-long carriers of coagu-
lase positive Staph. aureus. Especially in CRSwNP [69]
Staph. aureus colonizes the middle nasal meatus and
the surface of the nasal polyps. The colonization rates
are very high with 67 and 87% of the patients with
CRSwNP and asthma or NERD, respectively.
Staph. aureus does not only colonize the mucosa but
produces biofilms adhering at the inflamed and damaged
mucosa in order to serve as reservoir for planktonic
germs. Every now and again single germs are released
from the biofilms that protect, inform, and nourish germs
as three-dimensional structures. Those germs re-infect
the mucosa [121]. By means of PNA-FISH (a peptide
nucleic acid fluorescence in situ hybridization technique)
intramucosal Staph. aureus can be identified very spe-
cifically that is found intracellularly only the tissue of
CRSwNP patients [139]. The germ can also be present
as “small colony variant”, a sleeping variant with low
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Figure 7: Inferior turbinate, 24 hours after infection with rhinovirus (HRV 16, red) and Staph. aureus (green). The basalmembrane
is marked by the dotted line. Staph. aureus uses the epithelial damage caused by the infection with HRV 16 and infiltrated the
mucosa.
metabolism, or replicate in epithelial cells of nasal polyps
[140]. Those findings confirm the persisting character of
Staph. aureus infection and indicate its possible role as
amplificator of inflammations by means of its immune
proteome; beside the superantigens, Staph. aureus pro-
duces a multitude of proteins that may have an impact
on the human immune system.
Manipulation of the immune system means advantages
for the germs. We could show that the Th2 inflammation
of the nasal polyps favors the alternative activation of
macrophages to so-called M2 macrophages while those
immune cells are characterized by a reduced phagocytosis
and intracellular killing of germs including Staph. aureus
compared to the usually favored M1 macrophages [93].
This deficiency of the mucosal defense allow Staph.
aureus to colonize the mucosa and to enhance the Th2
immune reaction via different mechanisms.
Staph. aureus synthesizes and secretes numerous im-
mune proteins and enterotoxins, among those the clas-
sical enterotoxins (SEs) SEA, SEB, SEC, SED, SEE, and
toxic shock syndrome toxin-1 (TSST-1) [141]. SEs, also
known as superantigens, are able to activate T cells via
an antigen-unspecific binding to the variable β chain of
the T cell receptor which again allows a polyclonal activa-
tion of a high number of T cells with different character-
ization; up to 20% of the local T cells can be activated at
the same time instead of the usual rate of less than 0.1%
which may cause a “cytokine storm” [142]. This cytokine
storm can lead to the sudden death of the patient, and
in cases of chronic triggering it maintains a severe per-
sisting inflammatory reaction within the tissue. Further-
more, SEs can activate B cells, eosinophils, epithelial
cells and other cell populations which enhances the im-
mune globulin synthesis including IgE and the migration
of eosinophilic granulocytes in the tissue. The result is a
further Th2 polarization; SE-IgE positive nasal polyps have
a manifold increased IgE, ECP, and IL-5 compared to
SE-IgE negative polyps. Recently, we were able to provide
the proof of the local release of SEs and other immune
proteins from Staph. aureus in the tissue of nasal polyps
bymeans of proteomics (unpublished data). The changes
of the innate and adaptive immune response induced by
SEs [143] promote the survival of Staph. aureus. In an
animal model, SEs cannot only enhance Th2 mediated
inflammations of the airways but also induce them [144],
[145]. The intranasal application of allergens in mice
normally leads to development of tolerance; the addition
of SEB, however, leads to sensitization and formation of
an eosinophilic inflammation reaction of the upper and
lower airways [146]. We could show in human mucosa
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Figure 8: Staph. aureus can be localized in macrophages (M2) and identified as single cell in the tissue by in situ hybridization
(PNA-FISH).
that protein A and SEB from Staph. aureus lead to a sig-
nificant degranulation of mast cells and to the activation
of Th2 cells with consecutive release of the Th2 cytokines
IL-4, IL-5, and IL-13 [113]. These effects further influence
the T cell response in direction to Th2 and thus contribute
to a persisting, in particular eosinophilic inflammation of
the airways. Furthermore, SEB induces the release of
chemokines from epithelial cells which leads to the mi-
gration of granulocytes and their activation [147].
Recently, we could also prove that actually intramucosal
Staphylococcus germs amplify the production of IL-5 in
nasal polyps; after killing by antibiotics or Staphylococ-
cus-specific bacteriophages, the spontaneous IL-5 pro-
duction significantly reduced to the level of the polyps
that were not colonized by Staph. aureus (Bachert, in
press).
However, most important is the ability of staphylococcal
products like SEA and protein A to stimulate the produc-
tion of IgE antibodies [148], [149]. This B-cell stimulation
and transformation to plasma cells can also be observed
in tissue of nasal polyps [150]; in this context accumula-
tion of very high concentrations of IgE in the tissue results
while more than 5,000 kU/l IgE were measured in the
tissue of nasal polyps [102]. A real local IgE synthesis in
polyps may be organized via the formation of follicle-like
structure in the nasal polyp and the expression of a series
of mediators, that are important for immunoglobulin
synthesis, such as AID (activation-induced cytidine
deaminase) and BAFF, while the class switch of IgG to
IgE and the synthesis of specific IgE antibodies do not
require further lymphatic structures like lymph nodes
[104], [115], [151]. Recent examinations confirm this
hypothesis of a local immunoglobulin synthesis triggered
by SEs based on the proof of SE-IgE associated expression
of RAG1 and RAG2 [103].
Specific antibodies in polypous tissue are only a small
part (mostly less than 2%) of the total IgE which can only
hardly be identified or not identified at all. Nonetheless,
this polyclonal IgE is functional. According to the presence
of specific IgE antibodies in the tissue, as mast cell de-
granulation can be triggered by exposure to the corres-
ponding allergen, independent from the presence of the
IgE antibody in the serum [110]. This means that skin
tests or serum IgE measurements may be negative and
nonetheless a local degranulation of mast cells is
triggered by allergen contact; the IgE of nasal polyps can
be transferred to basophiles and also there it triggers a
specific activation of the basophiles (RBL SX38 cells) in
tests. This means the proof of the functionality of local
polyclonal IgE [110] and these observations can also be
transferred to the lower airways (Figure 8).
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2.6 From sinusitis to asthma
Around 40% of our patients with nasal polyposis also
suffer from asthma. The relation between CRS and
asthma has recently been proven for Europe in a multi-
centric study of the GALEN group [6]. This association
applies to the so-called late-onset asthma, however, the
patients are mostly not allergic. In a study on the defini-
tion of biochemical factors in the tissue of nasal polyps
associated with an increased risk for comorbid asthma
within the group of CRSwNP patients, it could be observed
that IL-5, IgE, and SE-IgE predict asthma. If SE-IgE is
present together with a high total IgE, the risk of comorbid
asthma is multiplied compared to SE-IgE negative
CRSwNP patients [99]. This observation could recently
be confirmed in an independent cluster analysis. Two of
10 CRS clusters were SE-IgE positive and had a rate of
comorbid asthma of 65–75% in contrast to CRs patients
whose comorbidity was less than 10% (Tomassen, in
press). Eosinophil but SE-IgE negative CRSwNP patients
suffer from asthma in 20–40% of the cases.
Also in patients with severe asthma, independent from
the diagnosis of polyposis, SE-IgE positivity is found signi-
ficantly more often (60%) than in control groups (13.0%,
P<0.001) [152]. A logistic regression analysis showed a
significantly higher risk of each type of asthma in SE-IgE
positive patients (OR 7.2 [95% confidence interval (CI)
2.7–19.1] or of severe asthma (OR 11.1 (95% CI
4.1–29.6)) in comparison to serum SE-IgE negative pa-
tients. According to skin test and serum IgE, 21% of the
patients with severe asthmawere non-atopic on inhalative
allergens; thus SE- IgE is a factor of “intrinsic” asthma
independent from an atopia. The application of oral cor-
ticosteroids, the number of hospitalizations because of
acute deterioration of the asthma, and the lung function
parameter FEV in 1% were all associated with SE-IgE in
the serum [152]. So we assume that Staph. aureus plays
amajor role in the pathophysiology of severe asthma and
SE-IgE in the serum marks the involvement of the germ
in the disease.
The sensitization against Staph. aureus enterotoxins is
rather frequent in Europe with a prevalence of nearly
30%. For the first time, this evaluation proved in a large
epidemiologic study performed in the population of the
EU that SE-IgE is clearly associated with asthma [153].
The results have recently been confirmed by a Korean
study group [154]. Another study performed in 240 older
patients with asthma (onset of the disease ≥40 years),
however, showed that the SE-IgE concentration in the
serum of the patients was significantly higher than in
control groups. Furthermore, SE-IgE correlated with the
total IgE, the eosinophilia in the sputum, with the severity
of the asthma, and the diagnosis of CRS (Song, in press).
The observations emphasize the role of SE-IgE in non-
atopic asthmatics with late onset and indicate the signi-
ficance of CRSwNP in this patient population.
Even in children and adolescents, associations between
SE-IgE and asthma were found, but in this age group they
are less important than in allergic diseases [155], [156]
(Sintobin, in press).
2.7 Biomechanisms of recurrences after
surgery
In the same way as concomitant asthma, also the prob-
ability of recurrences after total surgical removal might
be calculated from biopsies of CRSwNP patients. The
claim of completeness is based on the fact that in every
polyp an immunological memory is saved in the form of
so-calledmemory cells thatmaintain the existing immune
reaction unless they are surgically removed during an
intervention. Surgeries of recurrences in CRSwNP are
frequently performed. A follow-up examination over
12 years performed in Ghent, Belgium, revealed recur-
rences in nearly 80% of the patients requiring at least
intensive drug therapy (Gevaert, in press). A total of 36%
of the patients underwent at least one revision surgery
while the second interventions were performed over all
12 years. Corticosteroid resistant recurrences may even
develop 10 years after the first surgical intervention.
In a study performed over a shorter interval of 7 years,
we examined the immune profiles that were associated
with recurrences [9]. Biopsies of CRSwNP patients who
had developed a recurrence within this time were com-
pared to biopsies of patients who had not recurrence
within this same period of time. In all specimens the fol-
lowing parameters were measures: Th1, Th2, and Th17
cytokines, IgE, pro-inflammatory cytokines andmediators
of eosinophilic (ECP) and neutrophil inflammation (MPO).
Patients with recurrences had significantly higher concen-
trations of total IgE, SE-IgE, ECP, and IL-5 (OR 6.4) at first
surgery, whereas IFN-γ was significantly reduced (OR
0.047). The concentrations of IL-17, IL-6, TGF-β1, and IL-
1β did not differ between the groups. Asthma and NERD,
both Th2 weighted, as clinical parameters were alsomore
frequent in the group of recurrences.
The conclusion can be drawn that the polypous tissue of
patients with high risk of recurrences is different from
tissue with low risk for recurrence. The immune profile
that has to be antagonized can be deducted, and the
prognosis of the individual patient can be estimated.
Those findings show as well as observations of comorbid
asthma how heterogeneous chronic rhinosinusitis is and
which great influence is exercised by T helper cells on
the disease, their therapy, and prognosis. So we have to
move away from the idea that a simple classification into
CRSsNP and CRSwNP meets the differentiation of CRS.
Beside endoscope and computed tomography we will
have to introduce biomarkers into the diagnostic concepts
in order to meet the individual requirements in the sense
of personalized medicine.
This development has only started. It might be expected
that a better knowledge of the pathophysiology does not
only contribute to better predict the patients’ prognosis
but allows more targeted application of therapeutic op-
tions. While a CRS patient with severe fibrosis and mod-
erate neutrophil inflammationmay be treated sufficiently
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long-term with only one rather limited minimally invasive
intervention, the treatment of a patient with severe Th2
associated inflammation and significant edema will be
directed at removing the whole tissue of the nasal poly-
posis. This patients would then undergo a much more
aggressive and frequent follow-up as well as long-term
application of topic glukocorticosteroids, among others,
while the CRS patient might have experienced complete
healing after threemonths. For the first time we can offer
biomarkers, however, only in the tissue, later certainly
also in the serum that also allow to identify those patients
already before first surgery who would have to better
undergo drug therapy with humanized monoclonal anti-
bodies and other alternatives to be developed instead of
surgery.
This perspective will be further developed in the following
chapters while only the differentiation in clusters and
then their individual treatment modalities will be dis-
cussed.
3 Cluster analysis of CRS: definition
for CRS endotypes
Nowadays, statistical methods allow examining similar
disease patterns by analyzing certain clinical or biomed-
ical characteristics. This approach is called cluster ana-
lysis that under optimal conditions is independent from
the examiner. However, this method is already limited by
the fact that a certain choice of characteristics is made
for the analysis. The cluster analysis has promoted the
differentiation of severe asthma and it could show that
asthma has many different phenotypes [7] that have to
be treated in differentiated ways.
In the context of a European project called GALEN we
have collected the data of several hundreds of CRS pa-
tients. From a subgroup of patients (169 CRS and 89
healthy persons) we analyzed the tissue taken from the
paranasal sinuses. The analysis encompassed param-
eters from the field of remodeling, proinflammatory cy-
tokines, T cell cytokines for Th1, Th2, and Th17 lympho-
cytes, markers of eosinophilic and neutrophil activation
as well as IgE and SE-IgE. In this hierarchic cluster analys-
is, that was uninfluenced apart from that, exclusively tis-
sue markers were included. It was the objective to recog-
nize clusters of CRS based on biological patterns (To-
massen, in press). Only in a second step, the clinical
parameters were considered in order to verify the defined
clusters regarding their clinical relevance.
The following aspects could be identified: CRS can be
divided into 10 clusters that partly have overlapping
characteristics. The markers IgE, ECP, IL-5, SE-IgE, and
albumin are relevantly associated with each other, the
same is true for the markers IL-1, IL-8, and MPO. Thus
there is already a separation of neutrophil from eosino-
philic inflammations. However, it becomes obvious that
in every eosinophilic nasal polyp regularly also neutrophil
inflammation is found. In addition, the results show that
albuminmight be the connective link between eosinophil-
ic inflammation and edema in nasal polyposis while
neutrophil inflammation did not correlate with albumin.
A total of 6 of 10 clusters was characterized by an eosino-
philic and 8 by a neutrophil inflammation. Two of the
clusters were only neutrophil and two had no clear inflam-
matory pattern. This phenomenon is interesting because
it shows that CRS may be present even without evident
inflammation. Additionally, single clusters revealed in-
creased TNF-α, IFN-γ, or IL-17 concentrations that were
usually associated with neutrophil inflammations. Two of
those 6 clusters (cluster 9 and 10) with eosinophilic in-
flammation were SE-IgE positive and had increased IL-5,
IgE, and albumin levels in comparison to SE-IgE negative
clusters.
How can those clusters have a clinical relevance? Figure 9
shows the polypous part within each cluster on the left
side, while both non-inflammatory clusters were mainly
defined as CRSsNP and both IgE positive clusters as
CRSwNP according to clinical criteria. In the 6 clusters
with eosinophilic inflammation, at least 60% of the cases
had been assessed as CRSwNP. On the right side of the
figure, the part of comorbid asthma in the patients of the
single clusters is depicted. Whereas patients in clusters
1–4 had comorbid asthma in less than 20% of the cases,
this percentage in the clusters 9 and 10 is rather high
which shows the clinical relevance of the clusters.
Now, the endotypes can be deducted from the cluster
analysis that follow certain pathophysiological principles
and thus also the same group of therapeutics may be
applied, e.g. corticosteroids, but also biologic drugs.
Those endotypes are defined in Table 4. It becomes obvi-
ous that the eosinophilic endotypes are associated with
polyposis and comorbid asthma; however, those charac-
teristics are even clearer in the SE-IgE positive endotype.
Parallel, also the risk of recurrence after surgery in-
creases; also in this context the markers of Th2 inflam-
mation as well as the total IgE and SE-IgE that are asso-
ciated with the incidence of recurrences. Finally, there
are only the eosinophilic –mainly the strongly eosinophil-
ic/SE-IgE positive endotype that can be treated by applic-
ation of innovative therapeutic approaches or biologic
drugs that will be discussed later on. So these CRS endo-
types have a high clinical relevance and can be used for
the prognosis after surgery, prognosis of asthma, and fi-
nally prognosis of therapeutic response to targeted biolo-
gic drugs. This approach is the base for personalized
medicine in the management of CRS.
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Figure 9: Cluster analysis of CRS: in 8/10 clusters, neutrophil (in yellow) or eosinophilic (in red) inflammation is present. The
type with polyps and comorbid asthma (in red) correlates with the eosinophilic inflammation. Both SE-IgE positive clusters who
polyposis and comorbid asthma in the majority of the cases.
Table 4: Endotypes of CRS with clinical findings
3.1 Special phenotypes
3.1.1 Allergic fungal sinusitis (AFS)
Because of the fact that fungal spores are omnipresent,
they permanently enter in the airways by breathing and
are deposited on the mucosa. In isolates, Aspergillus,
Penicillium, Cladosporium, Candida, Aureobasidium, and
Alternaria are found most frequently. In the airways of
healthy people, they rarely become pathogenous, how-
ever, sometimes they are able to cause diseases. The
non-invasive type of mycotic CRS (fungus ball and allergic
fungal sinusitis) are diagnosed more frequently than in-
vasive types [157], [158]. In geographic areas with
warmer climate, the prevalence of allergic fungal sinusitis
is higher; the presence of fungi such asBipolaris spicifera,
Curvularia lunata, or Aspergillus species in the paranasal
sinuses is typical for the disease [158]. A high total IgE
concentration and a relevant eosinophilia in the blood
and the mucosal tissue are observed. In contrast, it is
unclear how those fungi induce this high IgE concentration
because they do not release stimulants for such IgE pro-
duction, as for example superantigens. More recent data
reveal the co-existence of the fungus Aspergillus
fumigatus with Staph. aureus in biofilms in patients
coming from Saudi Arabia while Staph. aureus is able to
trigger the polyclonal IgE production and the severe in-
flammatory reaction [159]. This observation was con-
firmed in cases of ABPA (allergic broncho-pulmonary as-
pergillosis), which is the equivalent of allergic fungal dis-
eases of the paranasal sinuses in the lower airways, by
the evidence of SE-IgE antibodies and their correlation
with the total IgE (L. Chishimba, Manchester, in coopera-
tion with our lab; publication is prepared). Those observa-
tions could lead to a new understanding of AFS and ABPA
and thus to a new therapeutic approach of Staph. aureus
and fungal germs (Figure 10).
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Figure 10: PNA-FISH depiction of Staph. aureus and Aspergillus fumigatus in patients with AFS
3.1.2 Aspirin sensitivity (NERD)
Often an intolerance against aspirin or non-steroidal anti-
inflammatory drugs (NSAID) is observed in patients suf-
fering from severe polyposis and asthma. The prevalence
of NERD (non-steroidal drug exacerbated respiratory dis-
ease) amounts to around 8% in the group of CRSwNP
and so it is significantly higher than in controls or CRSsNP.
More than 50% of the patients with asthma and aspirin
sensitivity also have polyps. NERD often develops as final
diagnosis, i.e. after persisting rhinitis in the third decade,
followed by asthma, nasal polyposis, finally aspirin intol-
erance occurs. About half of the patients suffer from
severe asthma depending from steroids. Surgery of the
paranasal sinuses is associated with a high incidence of
recurrences in aspirin-sensitive patients [9], [160].
In diseases of the paranasal sinuses, especially in
CRSwNP and NERD, the eicosanoid biosynthesis is mod-
ified. The imbalance is mainly characterized by an over-
expression of proinflammatory mediators, i.e. of leuko-
triene, and by a deficit of anti-inflammatory mediators
(prostaglandin E2 (PGE2) and lipoxin LXA4). Cysteinyl
leukotrienes (cys-LT) are important inductors of airway
inflammations [85], [161], [162]. In CRSwNP/NERD the
concentrations of thosemediators, of enzymes contribut-
ing to their biosynthesis (leukotriene synthase, LTC4S,
and 5-lipoxagenase, ALOX5) and their receptors are sig-
nificantly higher in comparison to CRSsNP and control
persons. They correlate with the number of activated
eosinophils and the concentrations of ECP, IL-5, and IL-
5Rα [85]. Furthermore, the ability of tissue of nasal polyps
to produce PGE2 and to up-regulate cyclooxygenases
(COX)-1, COX-2, and the prostaglandin E receptors EP2
is reduced under proinflammatory conditions [163]. The
expression of transcripts of prostaglandin E receptors
EP1 and EP3 is down- and the receptors EP2 and EP4
are up-regulated [164]. As the PGE2 concentrations are
reduced, the synthesis of leukotrienes (LT) is no longer
suppressed so that excessively many eosinophils and
high quantities of cys-LT are found [85]. PGE2 could also
influence remodeling of nasal tissue induced by fibro-
blasts [165]. Fibroblasts from nasal polyps produce sig-
nificantly higher quantities of constitutively expressed
COX-2 mRNA than fibroblasts of the inferior turbinates
which stimulated vascular dilatation and mucin produc-
tion [163].
The hematopoietic prostaglandin D synthase (hPGDS)
and the microsomal prostaglandin E synthase 1
(m-PGES-1) are both involved in the biosynthesis of PGD2,
however, they seem to be regulated otherwise in CRS
[166]. The expression pattern of PGD2 receptors such
as DP1 (D-prostanoid receptor 1) and CRTH2 (chemoat-
tractant receptor homologousmolecule) that is expressed
on T helper cells of type 2, is not yet clarified: in CRSwNP
the DP1 receptors is found mainly on tissue infiltrating,
inflammatory, and constitutive cells while CRTH2 ismostly
expressed in inflammatory cells (eosinophils and T cells)
[167]. In tissue of nasal polyps, the de novo synthesis of
PGD2 after stimulation via IgE is significantly up-regulated
[113], and this release promotes the release the migra-
tion of Th2 cells via a CRTH2-dependentmechanism [86].
As can be read in recent studies, the progression of in-
flammation in NERD airway diseases is associated with
a comparably reduced lipoxin synthesis while the mRNA
expression of ALOX15 and the consecutive LXA4 concen-
trations in CRSwNP patients is up-regulated [85]. ALOX15
is increased in the epithelium and subepithelium and
correlates positively with the number of activated eosino-
phils infiltrating the mucosa of the nasal polyps; NERD
patients have a reduced basal synthesis and reduced
ability to synthesize LXA4 under proinflammatory circum-
stances [85], [168].
4 Pharmaco-therapy of chronic
rhinosinusitis
The options that are currently recommended for therapy
of chronic rhinosinusitis (CRS) are summarized in interna-
tional and national guidelines. Most wide-spread are the
EPOS guidelines that have been established by an inter-
national team of experts (including myself) according to
criteria of evidence-based medicine [1]. Among those
treatment recommendations, topical and systemic
glukocorticosteroids, antibiotics as long-term therapy or
in cases of exacerbations as well as irrigations with saline
solution are found. If those options do not lead to success-
ful treatment or control of the symptoms, generally sur-
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Table 5: Evidence and recommendations of therapy in CRSsNP for adults (modified according to [1])
Table 6: Evidence and recommendations of therapy in CRSwNP for adults (modified according to [1])
gery is discussed. Postoperatively the same pharmaco-
therapeutics are continued or applied. The recommenda-
tions of the EPOS guidelines are summarized in Table 5
and Table 6 for CRS without nasal polyposis (CRSsNP)
and CRS with nasal polyposis (CRSwNP). They can be
completely downloaded via internet (http://
www.rhinologyjournal.com).
4.1 Chronic rhinosinusitis without nasal
polyps (CRSsNP)
Beside topical corticosteroids that are less effective in
CRSsNP before surgery because of the eosinophilic
character and the poor accessibility of the paranasal si-
nuses compared to CRSwNP, especially macrolides can
be discussed as low-dose long-term therapeutics
(>12 weeks) in CRSsNP. Even if the EPOS guidelines ac-
tually recommend macrolides unless IgE is not elevated
in the serum, an extensive European study with azithro-
mycin was negative [169]. However, there was criticism
about the patient selection (CRSsNP and CRSwNP) and
the missing consideration of serum IgE. A. Cervin who
was very committed to macrolide therapy summarized
30 years of experience with microlides and many open
studies in a recent review article that only two randomized
controlled studies had been performed that contradict
regarding their results. In one study that treated only
CRSsNP patients with roxithromycin versus placebo a
positive clinical effect was observed after 12 weeks of
treatment. However, recently major concern have arisen
in the context of macrolides as they might cause cardiac
arrhythmia [170]. In patients with risk factors such as a
prolonged QT intervals, bradycardia, hypokalemia, hypo-
magnesaemia etc. a long-term application of macrolides
cannot be recommended. Macrolides may also interact
with the cytochrome P450 system, cause ototoxicity, and
finally lead to development of resistances to macrolide
antibiotics in case of broad application [171].
4.2 Chronic rhinosinusitis with nasal
polyps (CRSwNP)
The application of topical corticosteroids is not disputed
in nasal polyps, as initial but also as postoperative ther-
apy. A dosage of 2x daily has to be observed which can
be reduced to 1x daily if reasonable when the disease is
controlled (for example no recurrence or no exacerbation
over at least one year after surgery). Because of the ne-
cessity of high dosage over several years, substances
with a low bioavailability should be preferred; according
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recommendations are included in a therapeutic index
[172]. In particular after surgery topical corticosteroid as
drops are recommended. They are applied in a position
with the head bent over or in the so-calledMecca position
in order to distribute optimally in the ethmoid region and
at the skull base. Recurrent polyps would preferably de-
velop in these regions.
The effectiveness of doxycycline (100 mg/d) has been
proven in a study of patients suffering from nasal polypos-
is over 20 days [123]. In this study, the effect of oral
corticosteroid therapy on symptoms, objective clinical as
well as biochemical parameters was compared to the
one of doxycycline. A placebo group was also created. In
this double blind randomized placebo-controlled study
47 patients with bilateral nasal polyposis either under-
went therapy with methyl-prednisolone in decreasing
dosage (from 32 to 16 to 8 mg every 5 days) or doxycyc-
line or placebo therapy (200 mg on the first day). The
patients weremonitored over 12weeks bymeans of peak
flow measurements, endoscopy, symptom scores, and
biomarkers in nasal secretion and peripheral blood. It
becameobvious thatmethyl-prednisolone and doxycycline
caused a significant reduction of the size of the polyps
compared to placebo. The effect of methyl-prednisolone
wasmaximal after 2 weeks but before the end of therapy
it already decreased and in total it was only significantly
different of placebo over 8 weeks. The effect of doxycyc-
line was less relevant but significant over the 12 weeks
of evaluation. Methyl-prednisolone significantly sup-
pressed the mediators ECP, IL-5, and IgE in nasal secre-
tion while doxycycline reduced the concentrations ofMPO,
ECP, and MMP-9.
We drew the conclusion of this study that an oral corticos-
teroid application has only a relatively short effect on
CRSwNP and that the side effects – especially in cases
of repeated application – are outweighed. In practice we
avoid oral corticosteroids as far as possible, in particular
directly preoperatively because the blood eosinophils
show a clear rebound effect after treatment. A high
number of circulating eosinophils a few weeks after sur-
gery must be considered as prognostically unfavorable.
Because of its positive effect on bacterial colonization
including Staph. aureus and biofilm formation as well as
because of reduction of MMPs (which contribute to the
development of edema in nasal polyposis) and IgE,
doxycycline is applied as long-term therapy for several
weeks, especially in the postoperative phase in order to
reduce edema and scar formation. The recommendations
of the ENT Department of Ghent are summarized in
Table 7.
It is obvious that those therapeutic principles are insuffi-
cient in some patients; even if a temporary improvement
of the complaints can be achieved it cannot be main-
tained over a longer period of time. Especially in patients
with CRSwNP pharmacotherapy is often not sufficient so
that surgery becomes necessary. Recurrences occur fre-
quently even after surgery so that some of the patients
have to undergo surgery several times in their lives. A
follow-up evaluation performed at the University of Ghent
in 42 patients older than 12 years estimated the recur-
rence rate over 12 years withmore than 75%while a total
of 36% of the patients had to undergo at least a second
intervention (Gevaert, in press). Another study fromGhent
had identified biomarkers previously that in the case of
necessary second intervention had already been in-
creased at the time of first surgery in comparison to pa-
tients who did not need second surgery (here over 7
years): IgE, SE-IgE, ECP, and IL-5 [9]. Those markers can
all be classified into the Th2 pattern. A high interferon
level (IFN-γ, Th1 cytokine) could be measured in patients
who did not require revision surgery. This suggests per-
spectives for a prognosis based on the biomarkers
measured at the occasion of the initial intervention. Fur-
thermore, it seems to be reasonable to apply therapeutics
that are effective for eosinophilic inflammations, in par-
ticular glucocorticosteroids, in this patient population
rather long and in higher doses. Additionally accompany-
ing measures against Staph. aureus increase the control
of the inflammation, for example by application of doxy-
cycline or mupirocin.
For patients who underwent complete resection with the
objective of the inflammatory tissue, who were treated
postoperatively with the above-mentioned therapeutics,
and who nonetheless had developed recurrences indicat-
ing surgery, the current treatment options are apparently
insufficient. Innovative approaches, actually in particular
so-called biologics, have to be considered. Regarding this
development, we are currently only at the beginning.
Currently only one humanized antibody is at our disposi-
tion limited to patients with the indication of severe aller-
gic asthma that cannot be treated otherwise. In the near
future, however, it might become obvious that those pa-
tients can already be identified before initial surgery by
determining biomarkers and – as surgery will most
probably not lead to the control of the disease – alternat-
ive therapy can be initiated immediately. Those reflections
have to be made also with regard to the background of
cost and benefit/risk analyses.
4.2.1 Specific reflections on allergic fungal
sinusitis (AFS)
Treatment starts with the complete resection of fungal
masses and colonized Staphylococcus as well as the
polypous mucosa from the paranasal sinuses. Attention
must be paid to complete removal and intensive postoper-
ative care like in other eosinophilic polyps. Just as eosino-
philic nasal polyps, the disease is also characterized by
a Th2 pattern; IL-5 is much increased such as IgE, there
are numerous secreting plasma cells and activated T cell
that apparently dispose of amemory for specific antigens.
The postoperative application of oral and topical corticos-
teroids supports the reduction and termination of the
immune response.
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Table 7: Treatment scheme for CRSsNP and CRSwNP from Ghent
4.2.2 Specific reflections on aspirin sensitivity
(NERD)
Also nasal polyps in aspirin sensitivity or NSAID exacer-
bated respiratory diseases show a clear Th2 pattern
where the markers of eosinophilic inflammation (IL-5,
ECP etc.) and also the tissue IgE are very high [173]. SE-
IgE is generally positive in the tissue and in cases of
asthma also in the serum. In comparison to normal poly-
posis with asthma, a deficient production of LXA4 is obvi-
ous which has anti-inflammatory activity. Apart from that,
surgery as well as conservative therapy of CRSwNP in
NERD follow the same principles as described above
(treatment scheme of Ghent, Table 7). Also the application
of omalizumab is not excluded.
Advocates of an adaptive deactivation must accept the
reply that only few centers perform provocation with as-
pirin or lysine aspirin which is a precondition of adaptive
deactivation; that a series of contraindications of provoca-
tion must be observed [174]; that the benefit of this
therapy, especially postoperatively, is not proven; and
that there are very contradictory ideas on effective but
well tolerable dosage of aspirin [174].
5 Biologics for the treatment of
asthma and chronic rhinosinusitis
It is clear that the pharmaceutical industry has experi-
enced an unparalleled development of pharmacologically
active peptide- and protein-based treatment approaches
for therapy of different diseases of the mucosa of the
airways and the gastrointestinal tract as well as systemic
diseases (for example Crohn’s disease,multiple sclerosis,
rheumatoid arthritis, just tomention some of them) during
the last years. The development of such biological sub-
stances requires profound knowledge of specific mo-
lecules of which the binding or “deactivation” has a relev-
ant therapeutic effect. Only then it makes sense to devel-
op antibodies and to humanize them secondarily, i.e. to
approximate them to the human antibody product as near
as possible. This process is incomparably expensive in
relation to the development of classic drugs. Currently
about 200 biologics are used for patients, further 400
are tested in studies. Among the indications, also severe
asthma is found that is very similar to chronic rhinosinus-
itis regarding its immune mechanisms, especially to the
Th2 pattern of CRSwNP.
Different innovative biologics are tested in clinical studies
for severe asthma and up to now finally one has been
approved. Omalizumab is applied today in a relatively
specific small group of patients with severe asthma, which
cannot be treated otherwise, under strict conditions. One
of the preconditions is that standard therapy with corticos-
teroids in high doses is not sufficient, that perennial
asthma is present, and that a lung specialist confirms
the indication of omalizumab. Omalizumab is a human-
izedmonoclonal antibody that is targeted against fee IgE.
It was primarily developed as antiallergic agent [175].
Meanwhile studies show that omalizumab is also effective
without the presence of allergy in cases of severe asthma
(the so-called intrinsic asthma) while those patients also
have increased IgE serum levels (see above) that are not
targeted against inhalative allergens. Insofar the limita-
tions of the authorities regarding the application of
omalizumab are already obsolete.
Also for chronic rhinosinusitis the single state-of-the-art
studies (DBRPC) with biologics have been performed, up
to now always in Ghent (Coordinating investigator: Claus
Bachert); reports on the experiences with omalizumab
have also been made by other departments. Among the
tested humanized antibodies, also anti-IgE (omalizumab),
anti-IL-5 (reslizumab and mepolizumab) as well as anti-
IL-4/13 (dupilumab) can be found. The target molecules
were targeted against Th2 associated mediators each.
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The studies reveal that the mentioned biologics are
therapeutically effective in 60-80% of the patients. In the
future, biomarkers shall help to increase this response
rate. Without any doubt, the studies can also be valued
as proof-of-concept for the possibility of targeted therapy
of Th2 associated mediators in cases of eosinophilic
chronic rhinosinusitis with nasal polyps with or without
concomitant asthma.
Table 8 and Table 9 give an overview of possible target
molecules for the treatment of Th2 associated respiratory
diseases (CRSwNP and asthma) according to the litera-
ture available today.
5.1 Anti-IgE (Omalizumab)
The discovery of high concentrations of IgE in nasal polyps
[115], [176] and the understanding that those IgE anti-
bodies are polyclonal and still functional [110], has justi-
fied a therapeutic attempt with omalizumab, a humanized
monoclonal antibody against free IgE. After positive re-
ports on single cases [177], the first smaller DBPCR study
with omalizumab in chronic rhinosinusitis, however, had
negative results; the reason was probably that patient
selection was made too inhomogeneously because also
patients without nasal polyposis were included where IgE
does not play a major role [178].
The effect of omalizumab is based on binding to the Cε3
region of the Fc fragment of the IgE molecule; the same
structure also binds to the alpha chain of the highly affine
receptor (FcεR1) onmast cells and basophils. The binding
of omalizumab thus inhibits docking of IgE to the highly
affine receptor, but binds in complexes that circulate in
the blood for a long time and are finally degradated.
Hence, omalizumab does not only bind free IgE in the
serum but disarmsmast cells and basophils in the tissue
and blood that do no longer degranulate in cases of
contact with the allergen or do no longer induce anaphyl-
axis [179]. As consequence, the expression of FcεR1 on
these cells is reduced and the consecutive effects includ-
ing eosinophilia are less important. At the same time the
binding of IgE to the lowly affine receptor FcεRII is inhib-
ited which reduces the IgE induced antigen presentation
by dendritic cells. In this way the allergic reaction is again
significantly attenuated.
Today, omalizumab is mainly applied as successful ther-
apy in severe allergic asthma if asthma cannot be con-
trolled by conventional asthma therapy and the patient
is at risk because of exacerbations of his disease. Fre-
quently, there is the additional requirement that a peren-
nial allergen is proven, the meaningfulness of this claim
must be questioned. The dosage of omalizumab should
lead to a relevant reduction of the free IgE concentration
in the blood, at the same time also IgE in the serum de-
creases. The dosage is calculated based on the total IgE
in the blood (max. 1,500 kU/l) as well as the body weight
of the patient. In cases of severe asthma, omalizumab
leads to a significant reduction of the exacerbations of
the disease and consecutively to a reduction of hospital-
ization (as well as the associated costs). Furthermore, it
reduces the number and the impact of viral diseases es-
pecially in children [137]. Currently an evenmore effective
anti-IgE molecule is being approved.
Despite the previous work on local production of IgE in
nasal polyps and their functionality it was not clear if
omalizumab reached the poorly vascularized tissue of
nasal polyps in sufficient concentration and could develop
its therapeutic effect in the sense of reduction of the
nasal polyposis after binding of IgE. Additionally, about
half of the patients are not atopic so that again the
question of the importance of the IgE antibodies was
asked. In those patients, asthma was often not allergic
but classified as late-onset asthma. However, we had
already explained previously that an increased IgE or
SE-IgE in tissue of nasal polyps is found in 30–40% of
the patients with CRSwNP, significantly increasing the
risk of asthma [152]; furthermore we had also proven
the functionality of local IgE antibodies [110]. The effect-
iveness of omalizumab would be another proof of the
functionality of local IgE production in the upper and lower
airways and would support the role of a non-atopic IgE
synthesis induced by Staph. aureus.
The clinical effectiveness of omalizumab applied in the
usual doses for severe asthma was examined in patients
with severe polyposis and concomitant asthma (light to
moderate) [180]. Omalizumab significantly reduced the
score of nasal polyps (primary parameter) already after
8 weeks and after 16 weeks further reduction of the
nasal polyps was found of a total of 2.6 score points; this
corresponds to the effect of a therapy of 3 weeks with
oral glucocorticosteroids (32mg of methyl-prednisolone)
and thus it is clinically relevant. Further, omalizumab
significantly reduced the Lund-Mackay score, which
measures the involvement of the paranasal sinuses in
the disease, as well as the symptoms of the upper and
lower airways including nasal obstruction, rhinorrhea,
and smelling disorders, wheezing, and shortness of
breath. Also quality of life parameters significantly im-
provedwith omalizumab in comparison to placebo, includ-
ing the asthma quality of life (AQLQ). So it could be con-
firmed for the first time that the reduction of local IgE in
selected CRSwNP patients was a worthwhile therapeutic
objective.
Half of the patients treated with omalizumabwere positive
against inhalative allergens in the skin test and thus
characterized as allergic. The others had no allergies. Al-
though the number of patients in this study was limited
and further studies will be necessary to clarify the effect-
iveness especially of non-allergic patients, a comparative
analysis revealed a better response of non-allergic than
allergic patients, especially in cases of asthma symptoms.
Meanwhile, there are also reports on experiences with
non-allergic asthma that confirm our results [181].
In this way, omalizumab demonstrated its clinical effect-
iveness in patients with nasal polyps and concomitant
asthma over several weeks and it was well tolerated.
Known risks such as anaphylactic reactions occurring in
rare cases must be observed. Experiences in the clinic
with patients who were treated primarily because of
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Table 8: Biologics and other innovative therapeutic concepts for treatment of asthma
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Table 8: Biologics and other innovative therapeutic concepts for treatment of asthma
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Table 9: Biologics and other innovative therapeutic concepts for the treatment of CRSwNP
Figure 11: Changes of the nasal polyp score after a) methyl-prednisolone for 3 weeks (32/16/8 mg) and b) omalizumab
(recommended dose for asthma)
severe asthma and who had CRSwNP at the same time,
confirmed the positive effects on the growth of the nasal
polyps [182]. Nowadays we successfully apply omalizu-
mab in patients with corticosteroid resistant recurrences
of polyposis after at least one correctly performed surgery
of the paranasal sinuses (in the sense of complete resec-
tion of the polyps) and concomitant (mostly not severe)
asthma complaints. So this situation is outside asthma
indication and we justify the application with the failure
of conventional pharmacotherapy and surgery. Of course,
the currently (still) high costs of the treatment have to be
included in the indication (Figure 11).
5.2 Anti-IL5 (Reslizumab, Mepolizumab)
About 80–85% of the nasal polyps in Europe, but only
10–50% of the polyps in Asia, have a Th2 inflammation
pattern with prominent eosinophilia, expression of inter-
leukin-5, and typical chemokines as well as activation
markers for eosinophilic granulocytes. As IL-5 plays a key
role in chemotaxis, differentiation, activation, and the
survival of eosinophils and as those cells represent such
a prominent characteristic in the polyps, the antagonism
of IL-5 could offer a therapeutic chance. However, it was
unclear if anti-IL-5 really reached the polyps and led to a
reduction of eosinophils with diminution of the nasal
polyps because polypous formations are also possible
without eosinophilia and the association of eosinophils
with edema is unclear.
In 1997, IL-5 was identified as key cytokine in nasal
polyposis [100]; among a series of cytokines, IL-5 was
most clearly associated with eosinophilia in nasal polyps
and could be proven immunohistochemically also in
eosinophils so that the cells themselves could be identi-
fied as source of the cytokine. In the same year we could
also show in an ex-vitro model that anti-IL-5 antibodies,
but not anti-IL-3 or anti-GM-CSF lead to cellular death
(apoptosis) of the eosinophils [120]. Later, it could also
be revealed that the regulation of IL-5 receptors plays a
significant role in the localization of the cells in nasal
polyps [183]. A first pilot study with reslizumab, a human-
ized anti-IL-5 antibody, showed a significant reduction of
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the size of the polyps in about 50% of the non-selected
patients after only one intravenous injection. A high IL-5
level in nasal secretion seemed to predict the therapeutic
response and also clearly decreased under verum therapy
[184]. Hence, the principle of IL-5 antagonismwas estab-
lished in eosinophilic nasal polyps.
In a second study, this time with 2 IV injections of 750mg
of mepolizumab, of 30 patients with severe nasal poly-
posis (Davos 3-4 or recurrence after surgery) even with
topical corticosteroids the results were mostly confirmed
[101]. After 8 weeks, a significant reduction of the polyp
score of at least one point was found in 60% of the pa-
tients treated with mepolizumab as well as a significant
reduction of the CT score. Those patients who had a re-
duction of the polyp score of at least one point (“respon-
ders”) observed a remaining effect over nearly one year.
So mepolizumab had a clinically relevant and in selected
patients also long-lasting effect on nasal polyposis that
did no longer respond to topical corticosteroids and thus
would have had to undergo surgery. Like omalizumab,
the quality of the effectiveness can certainly be con-
sidered as new dimension of therapeutic possibilities in
nasal polyposis. Again, mepolizumab was well tolerated.
Another long-term study with mepolizumab (principal in-
vestigator: Claus Bachert) has just been closed. The res-
ults are expected to be present in 2015. In the same
year, also the approval of mepolizumab for asthma can
be expected. However, currently it is still unclear if the
drug will be approved for nasal polyps.
5.3 Anti-IL-4/-13 (Dupilumab)
As severe persisting respiratory diseases like CRSwNP
and asthma must be classified as Th2 inflammations,
innovative therapeutic approaches focus on Th2-associ-
ated cytokines. Beside interleukin-5, also IL-4 and IL-13
must be mentioned. Both cytokines act via two different
receptors that partly overlap in their functions and they
both contain the alpha sub-unit of the IL-4 receptor. The
type 1 receptor that can only activated by IL-4 is mainly
expressed on lymphocytes and regulates the differenti-
ation of those cells. The type 2 receptor that is activated
by IL-4 and IL-13 is expressed by a multitude of cells and
has different functions, among them the production of
the mucous secretion that is typical for nasal polyps.
Dupilumab (SAR231893/REGN668) is a humanized an-
tibody against the alpha sub-unit of the IL-4 receptor and
can inhibit the effect of both cytokines, IL-4 and IL-13.
An investigation performed in the USA on severe asthma,
the application of dupilumab could reduce the number
of asthma exacerbations by 87% in comparison to
placebo [185]. In this study, the patients were deprived
of their asthma medication which led to a significant in-
crease of exacerbations in the placebo group but not in
the verum group. The pulmonary function in the verum
group improved significantly. Furthermore it could be
observed that different biomarkers of eosinophilic inflam-
mation (FeNO, serum-IgE as well as the chemokines eo-
taxin-3 and TARC) were significantly reduced in the serum
which confirms the biological activity of dupilumab. The
clinical effect size of dupilumab seemed to be higher as
the one of other biologics. As IL-4 and IL-13 also play a
role in the pathogenesis of nasal polyps, we have per-
formed a DBPCR study on the effectiveness and security
of dupilumab in patients with CRSwNP with at least 5/8
score points in the polyp score with or without concomit-
ant asthma. A total of 60 patients with bilateral nasal
polyposis despite double dose of topical corticosteroids
(mometasone furoate 2x daily) were observed for 4 weeks
with topical corticosteroids and then they were treated
either with 300mg of subcutaneous dupilumab per week
or placebo for additional 16 weeks. In the verum group
the polyp score significantly decreased of 1.9 points
compared to placebo (–0.3); also the CT score according
to Lund and Mackay was significantly reduced (–8.8).
The volume of the polyps in the maxillary sinuses was
reduced by 32%, the SNOT-22 and the UPSIT smelling
test revealed a significant effect compared to placebo.
More than half of the patients respondedwith a reduction
of the polyp score of at least 2 points (nearly similar to
the effectiveness of 3 weeks of oral application of cor-
ticosteroids). The symptoms like nasal obstruction,
rhinorrhea, and the subjective as well as objective
smelling significantly improved in the verum group as
also the nasal peak flow (PNIF, improvement of 60%).
Patients with asthma achieved a significantly improved
pulmonary function (FEV1) and asthma control test (ALQ-
5) in comparison to placebo. Patients with asthma also
had a better reduction of the score of polyps compared
to the total group (–2.4 score points in comparison to
placebo). 56% of the patients had a reduction of the score
of nasal polyps of more than 2 points.
Biomarkers of eonsinophilic inflammation were also sig-
nificantly reduced, among them IgE, TARC, and eotaxin-
3; in contrast to anti-IL-5, however, the absolute number
of eosinophils in the blood died not decrease. The action
profile of both biologics can be well differentiated while
the clinical effectiveness of dupilumab seems to be su-
perior to mepolizumab with comparable tolerability.
The results of this study are consistent with previous in-
vestigations of severe asthma and atopical dermatitis
and they impressively confirm the potential of dupilumab
to inhibit each type of Th2 induced inflammation and to
reduce clinical complaints. For nasal polyps we could
confirm this fact by subjective as well as objective para-
meters as additional effect being superior to basic therapy
with topical corticosteroids. Also in this context the effect
size is similar to the one of oral corticosteroids. Compar-
able to omalizumab, the patients with asthma also benefit
from the significant improvement of their complaints re-
garding the lower airways.
5.4 Biomarkers
It is obvious that future ENT specialists will need other
diagnostic tools beside endoscopes and CT scans allowing
them to identify the endotype of each disease. Such sur-
rogate markers could be determined most simply in the
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serum of the patients, as for example the absolute num-
ber of eosinophils in the blood, ECP as marker of activa-
tion of those cells, the total IgE as parameter of local IgE
synthesis, IL-5Ra instead of IL-5 etc. Further possibilities
are probably also chemokines such as TARC, PARC,
eotaxin-3, or periostin. However, those markers are cer-
tainly increased in the tissue but – in contrast to asthma
where the lung has a bigger production surface – the
markers in the serum are often below the detection limit
which seriously impairs the sensitivity of the test.
A primary objective would be to identify the Th2 type in
the tissue. Probably even specific statements can be
given on the involvement of single cytokines such as IL-4
vs. IL-5. The more successfully the individual endotype
can be defined, the more precise is the statement about
the prognosis (recurrence, asthma) and a personalized
therapy can be started with prediction of the therapeutic
effect of the according biologic. It must not be forgotten
to mention that also other T helper cell reactions might
be interesting for therapeutic interventions such as for
example Th17, Tfh, Th22, and others. Currently large
European cohort studies are performed on the question
of serum markers.
5.5 Future approaches
There are a series of further therapeutic objectives as for
example the antagonization of single cytokines of Th2
inflammation or their receptors like the IL-5 receptor al-
pha, TSLP. But also the deactivation of certain cells, es-
pecially of IgE producing B cells via a particular structure
of the B cell binding molecule, M1 Prime, may even be a
superordinate aim of research.
Although the development of those biologics is very
promising, there are still some problems like for example
the high costs of production and development of those
substances, the necessity of systemic application, and
the long-term effects that sometimes cannot be excluded.
For instance, the question was discussed if omalizumab
might increase the risk of malignant diseases. This suspi-
cion could recently be disproved after many years of ap-
plication [183].
It would be ideal to prefer local applications in the airways
that minimizes the systemic risks, that achieves the
therapeutic goal with small quantities, and that is con-
sequently cheaper. As representatives of a series of such
local approaches, two different approaches will be dis-
cussed here that have already been tested in humans
and that provided the evidence of clinical effectiveness
in mucosal surfaces.
5.5.1 Gene silencing, GATA3 DNA-zymes
The Th2 endotype is characterized by the predominance
of activated Th2 cells that synthesize and release the
cytokines IL-4, IL-5, and IL-13. The expression and pro-
duction of those cytokines is controlled by the transcrip-
tion factor GATA-3 that is relevant for the differentiation
and activation of Th2 lymphocytes and is considered as
“master switch” for all Th2 associated diseases. GATA-3
is overexpressed in nasal polyps, in asthma, and in
atopic eczema. By reducing the released cytokines, a
deactivation of the “master switch” would block also
consecutive pathomechanisms such as for example the
IgE production.
An innovative approach could thus deactivate all Th2 cy-
tokines via a blockage of the transcription factor GATA-3
and also the associated phenomena of IgE production
and tissue eosinophilia [186]. As GATA-3 is expressed
intracellularly, so-called “antisense” or “silencing” tech-
niques could be applied; molecules would have to be
used the can penetrate the target cells (Th2). This ap-
proach was successful for GATA-3 via the development
of a GATA-3 DNA-zyme in the sense that the DNAmolecule
docks to the GATA-3 RNA and quasi “cuts it up” by means
of a catalytic enzyme. The DNA-zyme hdg40 is very stable
and highly specific, at the same time, however, it is very
active and easy to apply via inhalation or spray to the
mucosa. In our laboratory we could show that GATA-3
DNA-zyme is absorbed without further transportation
support in the T cells and significantly reduces the expres-
sion of GATA-3 RNA as well as IL-5 protein [187]. Applied
in an asthmamodel in humans, hgd40 led to a significant
reduction of the allergic immediate and late phases as
well as the markers associated with a Th2 reaction. Thus
it had a high potential in the treatment of Th2 associated
diseases including CRSwNP and asthma, but also allergic
rhinitis.
5.5.2 Genetically modified Lactococcus lactis
(GM-LL)
Instead of complex antibodies that have to be produced
and humanized in expensive processes in order to be
applicable systemically, it is also possible today to choose
approaches where proteins or their derivatives, for ex-
ample nano-proteins, are produced direction on the mu-
cosa by apathogenous bacteria. ActoGeniX, a spin-off of
the University of Ghent, Belgium, has established the
technology for development and production of genetically
modified L. lacti and shown their pre-clinical and clinical
applicability for a series of diseases, among them also
allergic diseases. Some advantages are the local applic-
ation, the possibility of producing every protein by GM-LL,
and finally the possibility to have produced several
therapeutically effective proteins by one single germ. This
approach is currently investigated in pre-clinical studies.
5.5.3 Final remarks on biologics
It became obvious that the therapeutic approaches pur-
sued up to now, as they are also summarized in the new
EPOS guidelines, do not lead to long-term control of the
symptoms or healing in all patients with their basic pillars
of corticosteroids, antibiotics, and surgery. It is especially
the group of Th2 associated diseases that is often accom-
panied by recurrences and comorbid asthma. The in-
creased expression of the transcription factor GATA-3,
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the increased production of IL-4, IL-5 and IL-13 as well
as an increased local production of IgE are characteristic
for this immunologic situation and at the same time they
indicate innovative objectives of intervention.
Biologics have a new opened dimension of effectiveness
in comparison to oral corticosteroids; the response occurs
more slowly but there effect is longer-lasting and they
can be applied for several years without accumulation or
side effects with comparable or even better response.
Permanent application of oral corticosteroids would un-
doubtedly lead to health detriment that cannot be accep-
ted. Currently, in particular the costs are an argument
against the application of biologics.
It is certain that biologics currently will not replace the
surgical possibilities where surgery leads to permanent
success, for example in the therapy of CRSsNP. On the
other hand, there are patients who suffer from severe
Th2 inflammation with high probability of recurrence and
the necessity of repeated interventions andwith comorbid
asthma where surgery cannot have a permanent effect
and so in those cases an alternative therapy should be
started. For those patients, biologics are a valuable altern-
ative to repeated surgical revision. They are able to control
the symptoms of the disease of the upper as well as the
lower airways which according to our experience is often
associated with a significantly increased quality of life.
We as ENT specialists, however, have to improve our
knowledge of immunology in order to have sufficient
knowhow in diagnostics and finally therapy with innovative
drugs. We have to integrate the principle of endotyping
at least in patients with severe respiratory diseases in
our daily practice, refine the diagnostics by means of
biomarkers, and understand the indications and side ef-
fects of biologics with the background of pathophysiology.
Only then we will be in a position to offer our patients the
possibilities of modern innovative treatment.
Notes
Conflict of interests
As principal investigator, Claus Bachert has contributed
to studies with topical and oral corticosteroids, antibiotics,
and biologics including omalizumab, reslizumab, mepoli-
zumab, and dupilumab.
Funding
Claus Bachert’s projects have been supported by the
Fund for Scientific Research Flanders (FWO-Vlaanderen:
Mandat 1841713N and Projecte 3G.0489.08,
Go39412N, G.0642.10N, G067512N), the University of
Ghent BOF14/GOA/019 and 01J01113, the Interuni-
versity Attraction Poles Program (IUAP) – Belgian State –
Belgian Science Policy P6/35 and P7/30, the European
Commission’s 6th and 7th Framework programs FP-6/7
GALEN and PREDICTA.
References
1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F,
Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens
H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera
L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R,
Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald
PJ. European Position Paper on Rhinosinusitis and Nasal Polyps
2012. Rhinol Suppl. 2012 Mar;(23):1-298.
2. Bachert C, Van Bruaene N, Toskala E, Zhang N, Olze H, Scadding
G, Van Drunen CM, Mullol J, Cardell L, Gevaert P, Van Zele T,
Claeys S, Halldén C, Kostamo K, Foerster U, Kowalski M, Bieniek
K, Olszewska-Ziaber A, Nizankowska-Mogilnicka E, Szczeklik A,
Swierczynska M, Arcimowicz M, Lund V, Fokkens W, Zuberbier
T, Akdis C, Canonica G, Van Cauwenberge P, Burney P, Bousquet
J. Important research questions in allergy and related diseases:
3-chronic rhinosinusitis and nasal polyposis - a GALEN study.
Allergy. 2009 Apr;64(4):520-33. DOI: 10.1111/j.1398-
9995.2009.01964.x
3. Tomassen P, Newson RB, Hoffmans R, Lötvall J, Cardell LO,
GunnbjörnsdóttirM, Thilsing T, Matricardi P, Krämer U,Makowska
JS, Brozek G, Gjomarkaj M, Howarth P, Loureiro C, Toskala E,
Fokkens W, Bachert C, Burney P, Jarvis D. Reliability of EP3OS
symptom criteria and nasal endoscopy in the assessment of
chronic rhinosinusitis--a GA² LEN study. Allergy. 2011
Apr;66(4):556-61. DOI: 10.1111/j.1398-9995.2010.02503.x
4. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J,
Bockelbrink A, Bousquet PJ, Brozek G, Bruno A, Dahlén SE,
Forsberg B, Gunnbjörnsdóttir M, Kasper L, Krämer U, Kowalski
ML, Lange B, Lundbäck B, Salagean E, Todo-Bom A, Tomassen
P, Toskala E, van Drunen CM, Bousquet J, Zuberbier T, Jarvis D,
Burney P. Chronic rhinosinusitis in Europe--an underestimated
disease. A GA²LEN study. Allergy. 2011 Sep;66(9):1216-23. DOI:
10.1111/j.1398-9995.2011.02646.x
5. Hamilos DL. Chronic rhinosinusitis: epidemiology and medical
management. J Allergy Clin Immunol. 2011 Oct;128(4):693-707.
DOI: 10.1016/j.jaci.2011.08.004
6. Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T,
Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek
G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer
U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J,
Bachert C, Fokkens W, Burney P. Asthma in adults and its
association with chronic rhinosinusitis: the GA2LEN survey in
Europe. Allergy. 2012 Jan;67(1):91-8. DOI: 10.1111/j.1398-
9995.2011.02709.x
7. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X,
D'Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM,
Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF,
Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum
SC, Bleecker ER; National Heart, Lung, and Blood Institute's
Severe Asthma Research Program. Identification of asthma
phenotypes using cluster analysis in the Severe AsthmaResearch
Program. Am J Respir Crit Care Med. 2010 Feb;181(4):315-23.
DOI: 10.1164/rccm.200906-0896OC
8. Dixon AE, Kaminsky DA, Holbrook JT, Wise RA, Shade DM, Irvin
CG. Allergic rhinitis and sinusitis in asthma: differential effects
on symptoms and pulmonary function. Chest. 2006
Aug;130(2):429-35. DOI: 10.1378/chest.130.2.429
9. Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in
initial immunoprofiles between recurrent and nonrecurrent
chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy.
2014 May-Jun;28(3):192-8. DOI: 10.2500/ajra.2014.28.4033
10. Bossé Y, Bacot F, Montpetit A, Rung J, Qu HQ, Engert JC,
Polychronakos C, Hudson TJ, Froguel P, Sladek R, Desrosiers M.
Identification of susceptibility genes for complex diseases using
pooling-based genome-wide association scans. HumGenet. 2009
Apr;125(3):305-18. DOI: 10.1007/s00439-009-0626-9
31/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
11. Hsu J, Avila PC, Kern RC, Hayes MG, Schleimer RP, Pinto JM.
Genetics of chronic rhinosinusitis: state of the field and directions
forward. J Allergy Clin Immunol. 2013 Apr;131(4):977-93, DOI:
10.1016/j.jaci.2013.01.028
12. Henmyr V, Vandeplas G, Halldén C, Säll T, Olze H, Bachert C,
Cardell LO. Replication study of genetic variants associated with
chronic rhinosinusitis and nasal polyposis. J Allergy Clin Immunol.
2014 Jan;133(1):273-5. DOI: 10.1016/j.jaci.2013.08.011
13. Kim SH, Park HS, Holloway JW, Shin HD, Park CS. Association
between a TGFbeta1 promoter polymorphism and rhinosinusitis
in aspirin-intolerant asthmatic patients. Respir Med. 2007
Mar;101(3):490-5. DOI: 10.1016/j.rmed.2006.07.002
14. Zhang Y, Endam LM, Filali-Mouhim A, Bossé Y, Castano R,
DesrosiersM. Polymorphisms in the nitric oxide synthase 1 gene
are associated with severe chronic rhinosinusitis. Am J Rhinol
Allergy. 2011 Mar-Apr;25(2):e49-54. DOI:
10.2500/ajra.2011.25.3588
15. Zuo L, Koozechian MS, Chen LL. Characterization of reactive
nitrogen species in allergic asthma. Ann Allergy Asthma Immunol.
2014 Jan;112(1):18-22. DOI: 10.1016/j.anai.2013.10.007
16. Lee RJ, Chen B, Redding KM, Margolskee RF, Cohen NA. Mouse
nasal epithelial innate immune responses to Pseudomonas
aeruginosa quorum-sensing molecules require taste signaling
components. Innate Immun. 2013 Sep;20(6):606-17. DOI:
10.1177/1753425913503386
17. Zhang Y, Endam LM, Filali-Mouhim A, Zhao L, Desrosiers M, Han
D, Zhang L. Polymorphisms in RYBP and AOAH genes are
associated with chronic rhinosinusitis in a Chinese population:
a replication study. PLoS ONE. 2012;7(6):e39247. DOI:
10.1371/journal.pone.0039247
18. Barnes KC, Grant A, Gao P, Baltadjieva D, Berg T, Chi P, Zhang
S, Zambelli-Weiner A, Ehrlich E, Zardkoohi O, Brummet ME,
Stockton M, Watkins T, Gao L, Gittens M, Wills-Karp M, Cheadle
C, Beck LA, Beaty TH, Becker KG, Garcia JG, Mathias RA.
Polymorphisms in the novel gene acyloxyacyl hydroxylase (AOAH)
are associated with asthma and associated phenotypes. J Allergy
Clin Immunol. 2006 Jul;118(1):70-7. DOI:
10.1016/j.jaci.2006.03.036
19. Cheong HS, Park SM, Kim MO, Park JS, Lee JY, Byun JY, Park BL,
Shin HD, Park CS. Genome-wide methylation profile of nasal
polyps: relation to aspirin hypersensitivity in asthmatics. Allergy.
2011 May;66(5):637-44. DOI: 10.1111/j.1398-
9995.2010.02514.x
20. Seiberling KA, Church CA, Herring JL, Sowers LC. Epigenetics of
chronic rhinosinusitis and the role of the eosinophil. Int Forum
Allergy Rhinol. 2012 Jan-Feb;2(1):80-4. DOI: 10.1002/alr.20090
21. Van Bruaene N, Derycke L, Perez-Novo CA, Gevaert P, Holtappels
G, De Ruyck N, Cuvelier C, Van Cauwenberge P, Bachert C. TGF-
beta signaling and collagen deposition in chronic rhinosinusitis.
J Allergy Clin Immunol. 2009 Aug;124(2):253-9. DOI:
10.1016/j.jaci.2009.04.013
22. Cho JS, Moon YM, Park IH, Um JY, Moon JH, Park SJ, Lee SH,
Kang HJ, Lee HM. Epigenetic regulation of myofibroblast
differentiation and extracellular matrix production in nasal polyp-
derived fibroblasts. Clin Exp Allergy. 2012 Jun;42(6):872-82.
DOI: 10.1111/j.1365-2222.2011.03931.x
23. Zhang XH, Zhang YN, Li HB, Hu CY, Wang N, Cao PP, Liao B, Lu
X, Cui YH, Liu Z. Overexpression of miR-125b, a novel regulator
of innate immunity, in eosinophilic chronic rhinosinusitis with
nasal polyps. Am J Respir Crit Care Med. 2012 Jan;185(2):140-
51. DOI: 10.1164/rccm.201103-0456OC
24. Johansson ME, Larsson JM, Hansson GC. The two mucus layers
of colon are organized by the MUC2 mucin, whereas the outer
layer is a legislator of host-microbial interactions. Proc Natl Acad
Sci USA. 2011 Mar;108 Suppl 1:4659-65. DOI:
10.1073/pnas.1006451107
25. Zhang Y, Wang X, Wang H, Jiao J, Li Y, Fan E, Zhang L, Bachert
C. TMEM16A-Mediated Mucin Secretion in IL-13-Induced Nasal
Epithelial Cells From Chronic Rhinosinusitis Patients. Allergy
Asthma Immunol Res. 2015 Jul;7(4):367-75. DOI:
10.4168/aair.2015.7.4.367
26. Avila P, Schleimer RP. Airway Epithelium. In: Kay AB, Kaplan AP,
Bousquet J, Holt PG, editors. Allergy and allergic diseases. 2nd
ed. Oxford: Wiley-Blackwell; 2008. DOI:
10.1002/9781444300918.ch16
27. LaudienM, Dressel S, Harder J, Gläser R. Differential expression
pattern of antimicrobial peptides in nasal mucosa and secretion.
Rhinology. 2011Mar;49(1):107-11. DOI: 10.4193/Rhino10.036
28. Meyer JE, Harder J, Sipos B, Maune S, Klöppel G, Bartels J,
Schröder JM, Gläser R. Psoriasin (S100A7) is a principal
antimicrobial peptide of the human tongue. Mucosal Immunol.
2008 May;1(3):239-43. DOI: 10.1038/mi.2008.3
29. Ramanathan M Jr, Lee WK, Spannhake EW, Lane AP. Th2
cytokines associated with chronic rhinosinusitis with polyps down-
regulate the antimicrobial immune function of human sinonasal
epithelial cells. Am J Rhinol. 2008 Mar-Apr;22(2):115-21. DOI:
10.2500/ajr.2008.22.3136
30. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA,
Reinhart TA, McAllister F, Edeal J, Gaus K, Husain S, Kreindler
JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura Y,
Kolls JK. IL-22 mediates mucosal host defense against Gram-
negative bacterial pneumonia. Nat Med. 2008 Mar;14(3):275-
81. DOI: 10.1038/nm1710
31. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen
M, Lehr HA, Hirth S, Weigmann B, Wirtz S, Ouyang W, Neurath
MF, Becker C. STAT3 links IL-22 signaling in intestinal epithelial
cells to mucosal wound healing. J Exp Med. 2009
Jul;206(7):1465-72. DOI: 10.1084/jem.20082683
32. Ramanathan M Jr, Spannhake EW, Lane AP. Chronic
rhinosinusitis with nasal polyps is associated with decreased
expression of mucosal interleukin 22 receptor. Laryngoscope.
2007 Oct;117(10):1839-43. DOI:
10.1097/MLG.0b013e31811edd4f
33. Peters M, Dudziak K, Stiehm M, Bufe A. T-cell polarization
depends on concentration of the danger signal used to activate
dendritic cells. Immunol Cell Biol. 2010 Jul;88(5):537-44. DOI:
10.1038/icb.2010.3
34. Lee RJ, Kofonow JM, Rosen PL, Siebert AP, Chen B, Doghramji
L, Xiong G, Adappa ND, Palmer JN, Kennedy DW, Kreindler JL,
Margolskee RF, Cohen NA. Bitter and sweet taste receptors
regulate human upper respiratory innate immunity. J Clin Invest.
2014 Mar;124(3):1393-405. DOI: 10.1172/JCI72094
35. Rogers GA, Den Beste K, Parkos CA, Nusrat A, Delgaudio JM,
Wise SK. Epithelial tight junction alterations in nasal polyposis.
Int Forum Allergy Rhinol. 2011 Jan-Feb;1(1):50-4. DOI:
10.1002/alr.20014
36. Zuckerman JD, LeeWY, DelGaudio JM, Moore CE, Nava P, Nusrat
A, Parkos CA. Pathophysiology of nasal polyposis: the role of
desmosomal junctions. Am J Rhinol. 2008 Nov-Dec;22(6):589-
97. DOI: 10.2500/ajr.2008.22.3235
37. Tieu DD, Peters AT, Carter RG, Carter RT, Suh L, Conley DB,
Chandra R, Norton J, Grammer LC, Harris KE, Kato A, Kern RC,
Schleimer RP. Evidence for diminished levels of epithelial
psoriasin and calprotectin in chronic rhinosinusitis. J Allergy Clin
Immunol. 2010 Mar;125(3):667-75. DOI:
10.1016/j.jaci.2009.11.045
38. Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A,
Wanke K, Kast JI, Akdis CA. Defective epithelial barrier in chronic
rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4.
J Allergy Clin Immunol. 2012 Nov;130(5):1087-96. DOI:
10.1016/j.jaci.2012.05.052
32/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
39. Meng J, Zhou P, Liu Y, Liu F, Yi X, Liu S, Holtappels G, Bachert C,
Zhang N. The development of nasal polyp disease involves early
nasal mucosal inflammation and remodelling. PLoS ONE.
2013;8(12):e82373. DOI: 10.1371/journal.pone.0082373
40. Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium:
at the interface of innate and adaptive immune responses. J
Allergy Clin Immunol. 2007 Dec;120(6):1279-84. DOI:
10.1016/j.jaci.2007.08.046
41. Claeys S, de Belder T, Holtappels G, Gevaert P, Verhasselt B, van
Cauwenberge P, Bachert C. Human beta-defensins and toll-like
receptors in the upper airway. Allergy. 2003 Aug;58(8):748-53.
DOI: 10.1034/j.1398-9995.2003.00180.x
42. Vandermeer J, Sha Q, Lane AP, Schleimer RP. Innate immunity
of the sinonasal cavity: expression of messenger RNA for
complement cascade components and toll-like receptors. Arch
Otolaryngol Head Neck Surg. 2004 Dec;130(12):1374-80. DOI:
10.1001/archotol.130.12.1374
43. Kawai T, Akira S. Toll-like receptors and their crosstalk with other
innate receptors in infection and immunity. Immunity. 2011
May;34(5):637-50. DOI: 10.1016/j.immuni.2011.05.006
44. Lane AP, Truong-Tran QA, Myers A, Bickel C, Schleimer RP. Serum
amyloid A, properdin, complement 3, and toll-like receptors are
expressed locally in human sinonasal tissue. Am J Rhinol. 2006
Jan-Feb;20(1):117-23.
45. Zhao CY, Wang X, Liu M, Jin DJ. Microarray gene analysis of Toll-
like receptor signaling elements in chronic rhinosinusitis with
nasal polyps. Int Arch Allergy Immunol. 2011;156(3):297-304.
DOI: 10.1159/000323767
46. Sun Y, Zhou B, Wang C, Huang Q, Zhang Q, Han Y, Dai W, Fan E,
Li Y. Biofilm formation and Toll-like receptor 2, Toll-like receptor
4, and NF-kappaB expression in sinus tissues of patients with
chronic rhinosinusitis. Am J Rhinol Allergy. 2012 Mar-
Apr;26(2):104-9. DOI: 10.2500/ajra.2012.26.3718
47. Kato A, Schleimer RP. Beyond inflammation: airway epithelial
cells are at the interface of innate and adaptive immunity. Curr
Opin Immunol. 2007 Dec;19(6):711-20. DOI:
10.1016/j.coi.2007.08.004
48. Bogefors J, Rydberg C, Uddman R, Fransson M, Månsson A,
Benson M, Adner M, Cardell LO. Nod1, Nod2 and Nalp3
receptors, new potential targets in treatment of allergic rhinitis?
Allergy. 2010 Oct;65(10):1222-6. DOI: 10.1111/j.1398-
9995.2009.02315.x
49. Rudack C, Steinhoff M, Mooren F, Buddenkotte J, Becker K, von
Eiff C, Sachse F. PAR-2 activation regulates IL-8 and GRO-alpha
synthesis by NF-kappaB, but not RANTES, IL-6, eotaxin or TARC
expression in nasal epithelium. Clin Exp Allergy. 2007
Jul;37(7):1009-22. DOI: 10.1111/j.1365-2222.2007.02686.x
50. Ossovskaya VS, Bunnett NW. Protease-activated receptors:
contribution to physiology and disease. Physiol Rev. 2004
Apr;84(2):579-621. DOI: 10.1152/physrev.00028.2003
51. Vroling AB, Fokkens WJ, van Drunen CM. How epithelial cells
detect danger: aiding the immune response. Allergy. 2008
Sep;63(9):1110-23. DOI: 10.1111/j.1398-9995.2008.01785.x
52. Rudack C, Sachse F, Albert N, Becker K, von Eiff C.
Immunomodulation of nasal epithelial cells by Staphylococcus
aureus-derived serine proteases. J Immunol. 2009
Dec;183(11):7592-601. DOI: 10.4049/jimmunol.0803902
53. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive
immune responses. Nat Immunol. 2004 Oct;5(10):987-95. DOI:
10.1038/ni1112
54. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of
immune responses. Curr Opin Immunol. 2005 Aug;17(4):359-
65. DOI: 10.1016/j.coi.2005.06.002
55. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know
about danger. J Leukoc Biol. 2007 Jan;81(1):1-5. DOI:
10.1189/jlb.0306164
56. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA,
Washburn NR, Devera ME, Liang X, Tör M, Billiar T. The grateful
dead: damage-associated molecular pattern molecules and
reduction/oxidation regulate immunity. Immunol Rev. 2007
Dec;220:60-81. DOI: 10.1111/j.1600-065X.2007.00579.x
57. Piccinini AM, Midwood KS. DAMPening inflammation by
modulating TLR signalling. Mediators Inflamm.
2010;2010:672395. DOI: 10.1155/2010/672395
58. Van Crombruggen K, Holtappels G, De Ruyck N, Derycke L,
Tomassen P, Bachert C. RAGE processing in chronic airway
conditions: involvement of Staphylococcus aureus and ECP. J
Allergy Clin Immunol. 2012 Jun;129(6):1515-21.e8. DOI:
10.1016/j.jaci.2012.02.021
59. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-
associated molecular-pattern molecules (DAMPs) and redox.
Trends Immunol. 2007 Oct;28(10):429-36. DOI:
10.1016/j.it.2007.08.004
60. Hudson BI, Carter AM, Harja E, Kalea AZ, ArrieroM, Yang H, Grant
PJ, Schmidt AM. Identification, classification, and expression of
RAGE gene splice variants. FASEB J. 2008 May;22(5):1572-80.
DOI: 10.1096/fj.07-9909com
61. YamakawaN, Uchida T, MatthayMA,Makita K. Proteolytic release
of the receptor for advanced glycation end products from in vitro
and in situ alveolar epithelial cells. Am J Physiol Lung Cell Mol
Physiol. 2011 Apr;300(4):L516-25. DOI:
10.1152/ajplung.00118.2010
62. Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth PP, Martin E,
Weigand MA. Bench-to-bedside review: The inflammation-
perpetuating pattern-recognition receptor RAGE as a therapeutic
target in sepsis. Crit Care. 2008;12(1):201. DOI:
10.1186/cc6164
63. Bierhaus A, Humpert PM, MorcosM, Wendt T, Chavakis T, Arnold
B, Stern DM, Nawroth PP. Understanding RAGE, the receptor for
advanced glycation end products. J Mol Med. 2005
Nov;83(11):876-86. DOI: 10.1007/s00109-005-0688-7
64. Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. Soluble receptor
for advanced glycation end products triggers a proinflammatory
cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum.
2006 Dec;54(12):3898-907. DOI: 10.1002/art.22217
65. Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ,
Fattman CL, Ramsgaard L, Richards TJ, Loutaev I, Nawroth PP,
Kasper M, Bierhaus A, Oury TD. A role for the receptor for
advanced glycation end products in idiopathic pulmonary fibrosis.
Am J Pathol. 2008 Mar;172(3):583-91. DOI:
10.2353/ajpath.2008.070569
66. Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP.
Promotion of cell adherence and spreading: a novel function of
RAGE, the highly selective differentiation marker of human
alveolar epithelial type I cells. Cell Tissue Res. 2006
Mar;323(3):475-88. DOI: 10.1007/s00441-005-0069-0
67. Li X, Meng J, Qiao X, Liu Y, Liu F, Zhang N, Zhang J, Holtappels
G, Luo B, Zhou P, Zheng Y, Lin P, Liu S, Bachert C. Expression of
TGF, matrix metalloproteinases, and tissue inhibitors in Chinese
chronic rhinosinusitis. J Allergy Clin Immunol. 2010
May;125(5):1061-8. DOI: 10.1016/j.jaci.2010.02.023
68. Queisser MA, Kouri FM, Königshoff M, Wygrecka M, Schubert U,
Eickelberg O, Preissner KT. Loss of RAGE in pulmonary fibrosis:
molecular relations to functional changes in pulmonary cell types.
Am J Respir Cell Mol Biol. 2008 Sep;39(3):337-45. DOI:
10.1165/rcmb.2007-0244OC
33/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
69. Van Zele T, Gevaert P, Watelet JB, Claeys G, Holtappels G, Claeys
C, van Cauwenberge P, Bachert C. Staphylococcus aureus
colonization and IgE antibody formation to enterotoxins is
increased in nasal polyposis. J Allergy Clin Immunol. 2004
Oct;114(4):981-3. DOI: 10.1016/j.jaci.2004.07.013
70. Chen Y, Akirav EM, ChenW, Henegariu O, Moser B, Desai D, Shen
JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM,
Clynes R, Herold KC. RAGE ligation affects T cell activation and
controls T cell differentiation. J Immunol. 2008 Sep;181(6):4272-
8. DOI: 10.4049/jimmunol.181.6.4272
71. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen
MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and
Mrp14 are endogenous activators of Toll-like receptor 4,
promoting lethal, endotoxin-induced shock. Nat Med. 2007
Sep;13(9):1042-9. DOI: 10.1038/nm1638
72. Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W,
Klenner L, Kuhn A, Foell D, Sorokin L, Luger TA, Roth J, Beissert
S. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial
in the development of autoreactive CD8+ T cells. Nat Med. 2010
Jun;16(6):713-7. DOI: 10.1038/nm.2150
73. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J,
Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT. RAGE
(Receptor for Advanced Glycation Endproducts), RAGE ligands,
and their role in cancer and inflammation. J Transl Med.
2009;7:17. DOI: 10.1186/1479-5876-7-17
74. Richer SL, Truong-Tran AQ, Conley DB, Carter R, Vermylen D,
Grammer LC, Peters AT, Chandra RK, Harris KE, Kern RC,
Schleimer RP. Epithelial genes in chronic rhinosinusitis with and
without nasal polyps. Am J Rhinol. 2008May-Jun;22(3):228-34.
DOI: 10.2500/ajr.2008.22.3162
75. White ES, Baralle FE, Muro AF. New insights into form and
function of fibronectin splice variants. J Pathol. 2008
Sep;216(1):1-14. DOI: 10.1002/path.2388
76. Van Crombruggen K, Zhang N, Gevaert P, Tomassen P, Bachert
C. Pathogenesis of chronic rhinosinusitis: inflammation. J Allergy
Clin Immunol. 2011 Oct;128(4):728-32. DOI:
10.1016/j.jaci.2011.07.049
77. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J,
Chow JC, Strauss JF 3rd,. The extra domain A of fibronectin
activates Toll-like receptor 4. J Biol Chem. 2001
Mar;276(13):10229-33. DOI: 10.1074/jbc.M100099200
78. Menzies BE. The role of fibronectin binding proteins in the
pathogenesis of Staphylococcus aureus infections. Curr Opin
Infect Dis. 2003 Jun;16(3):225-9. DOI:
10.1097/01.qco.0000073771.11390.75
79. Henderson B, Nair S, Pallas J, Williams MA. Fibronectin: a
multidomain host adhesin targeted by bacterial fibronectin-
binding proteins. FEMSMicrobiol Rev. 2011 Jan;35(1):147-200.
DOI: 10.1111/j.1574-6976.2010.00243.x
80. Hammad H, Lambrecht BN. Dendritic cells and airway epithelial
cells at the interface between innate and adaptive immune
responses. Allergy. 2011 May;66(5):579-87. DOI:
10.1111/j.1398-9995.2010.02528.x
81. Hazenberg MD, Spits H. Human innate lymphoid cells. Blood.
2014 Jul;124(5):700-9. DOI: 10.1182/blood-2013-11-427781
82. Mjösberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM,
Piet B, Fokkens WJ, Cupedo T, Spits H. Human IL-25- and IL-33-
responsive type 2 innate lymphoid cells are defined by expression
of CRTH2 and CD161. Nat Immunol. 2011Nov;12(11):1055-62.
DOI: 10.1038/ni.2104
83. Shikotra A, Choy DF, Ohri CM, Doran E, Butler C, Hargadon B,
Shelley M, Abbas AR, Austin CD, Jackman J, Wu LC, Heaney LG,
Arron JR, Bradding P. Increased expression of immunoreactive
thymic stromal lymphopoietin in patients with severe asthma. J
Allergy Clin Immunol. 2012 Jan;129(1):104-11.e1-9. DOI:
10.1016/j.jaci.2011.08.031
84. Barnig C, Cernadas M, Dutile S, Liu X, Perrella MA, Kazani S,
Wechsler ME, Israel E, Levy BD. Lipoxin A4 regulates natural
killer cell and type 2 innate lymphoid cell activation in asthma.
Sci Transl Med. 2013 Feb;5(174):174ra26. DOI:
10.1126/scitranslmed.3004812
85. Pérez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P,
Bachert C. Prostaglandin, leukotriene, and lipoxin balance in
chronic rhinosinusitis with and without nasal polyposis. J Allergy
Clin Immunol. 2005 Jun;115(6):1189-96. DOI:
10.1016/j.jaci.2005.02.029
86. Pérez-Novo CA, Holtappels G, Vinall SL, Xue L, Zhang N, Bachert
C, Pettipher R. CRTH2 mediates the activation of human Th2
cells in response to PGD(2) released from IgE/anti-IgE treated
nasal polyp tissue. Allergy. 2010 Mar;65(3):304-10. DOI:
10.1111/j.1398-9995.2009.02204.x
87. Demedts IK, Bracke KR,Maes T, Joos GF, Brusselle GG. Different
roles for human lung dendritic cell subsets in pulmonary immune
defense mechanisms. Am J Respir Cell Mol Biol. 2006
Sep;35(3):387-93. DOI: 10.1165/rcmb.2005-0382OC
88. Reinartz SM, van Tongeren J, van Egmond D, de Groot EJ,
Fokkens WJ, van Drunen CM. Dendritic cells in nasal mucosa of
subjects with different allergic sensitizations. J Allergy Clin
Immunol. 2011 Oct;128(4):887-90. DOI:
10.1016/j.jaci.2011.06.001
89. Pezato R, Pérez-Novo CA, Holtappels G, De Ruyck N, Van
Crombruggen K, De Vos G, Bachert C, Derycke L. The expression
of dendritic cell subsets in severe chronic rhinosinusitis with
nasal polyps is altered. Immunobiology. 2014 Sep;219(9):729-
36. DOI: 10.1016/j.imbio.2014.05.004
90. Martinez FO, Helming L, Gordon S. Alternative activation of
macrophages: an immunologic functional perspective. Annu Rev
Immunol. 2009;27:451-83. DOI:
10.1146/annurev.immunol.021908.132532
91. Sica A, Mantovani A. Macrophage plasticity and polarization: in
vivo veritas. J Clin Invest. 2012 Mar;122(3):787-95. DOI:
10.1172/JCI59643
92. Gordon S. Alternative activation of macrophages. Nat Rev
Immunol. 2003 Jan;3(1):23-35. DOI: 10.1038/nri978
93. Krysko O, Holtappels G, Zhang N, KubicaM, Deswarte K, Derycke
L, Claeys S, Hammad H, Brusselle GG, Vandenabeele P, Krysko
DV, Bachert C. Alternatively activatedmacrophages and impaired
phagocytosis of S. aureus in chronic rhinosinusitis. Allergy. 2011
Mar;66(3):396-403. DOI: 10.1111/j.1398-9995.2010.02498.x
94. Peterson S, Poposki JA, Nagarkar DR, Chustz RT, Peters AT, Suh
LA, Carter R, Norton J, Harris KE, Grammer LC, Tan BK, Chandra
RK, Conley DB, Kern RC, Schleimer RP, Kato A. Increased
expression of CC chemokine ligand 18 in patients with chronic
rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2012
Jan;129(1):119-27.e1-9. DOI: 10.1016/j.jaci.2011.08.021
95. Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van
Cauwenberge P, Bachert C. Differentiation of chronic sinus
diseases by measurement of inflammatory mediators. Allergy.
2006 Nov;61(11):1280-9. DOI: 10.1111/j.1398-
9995.2006.01225.x
96. Lan F, Zhang N, Zhang J, Krysko O, Zhang Q, Xian J, Derycke L,
Qi Y, Li K, Liu S, Lin P, Bachert C. Forkhead box protein 3 in
human nasal polyp regulatory T cells is regulated by the protein
suppressor of cytokine signaling 3. J Allergy Clin Immunol. 2013
Dec;132(6):1314-21. DOI: 10.1016/j.jaci.2013.06.010
97. Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels
G, DeRuyck N, Van Cauwenberge P, Bachert C. Different types
of T-effector cells orchestrate mucosal inflammation in chronic
sinus disease. J Allergy Clin Immunol. 2008 Nov;122(5):961-8.
DOI: 10.1016/j.jaci.2008.07.008
34/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
98. Derycke L, Eyerich S, Van Crombruggen K, Pérez-Novo C,
Holtappels G, Deruyck N, Gevaert P, Bachert C. Mixed T helper
cell signatures in chronic rhinosinusitis with and without polyps.
PLoS ONE. 2014;9(6):e97581. DOI:
10.1371/journal.pone.0097581
99. Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge
P, Liu S, Lin P, Bousquet J, Van Steen K. Presence of IL-5 protein
and IgE antibodies to staphylococcal enterotoxins in nasal polyps
is associated with comorbid asthma. J Allergy Clin Immunol. 2010
Nov;126(5):962-8. DOI: 10.1016/j.jaci.2010.07.007
100. Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis
is upregulated in human nasal polyp tissue. J Allergy Clin
Immunol. 1997 Jun;99(6 Pt 1):837-42. DOI: 10.1016/S0091-
6749(97)80019-X
101. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T,
Acke F, De Ruyck N, Blomme K, Sousa AR, Marshall RP, Bachert
C. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment
option for severe nasal polyposis. J Allergy Clin Immunol. 2011
Nov;128(5):989-95.e1-8. DOI: 10.1016/j.jaci.2011.07.056
102. Van Zele T, Gevaert P, Holtappels G, van Cauwenberge P, Bachert
C. Local immunoglobulin production in nasal polyposis is
modulated by superantigens. Clin Exp Allergy. 2007
Dec;37(12):1840-7. DOI: 10.1111/j.1365-2222.2007.02838.x
103. Gevaert P, Nouri-Aria KT, Wu H, Harper CE, Takhar P, Fear DJ,
Acke F, De Ruyck N, Banfield G, Kariyawasam HH, Bachert C,
DurhamSR, Gould HJ. Local receptor revision and class switching
to IgE in chronic rhinosinusitis with nasal polyps. Allergy. 2013
Jan;68(1):55-63. DOI: 10.1111/all.12054
104. Mechtcheriakova D, Sobanov Y, Holtappels G, Bajna E, Svoboda
M, Jaritz M, Bachert C, Jensen-Jarolim E. Activation-induced
cytidine deaminase (AID)-associated multigene signature to
assess impact of AID in etiology of diseases with inflammatory
component. PLoS ONE. 2011;6(10):e25611. DOI:
10.1371/journal.pone.0025611
105. Kato A, Peters A, Suh L, Carter R, Harris KE, Chandra R, Conley
D, Grammer LC, Kern R, Schleimer RP. Evidence of a role for B
cell-activating factor of the TNF family in the pathogenesis of
chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol.
2008 Jun;121(6):1385-92. DOI: 10.1016/j.jaci.2008.03.002
106. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev
Immunol. 2009 Jul;9(7):491-502. DOI: 10.1038/nri2572
107. Kallies A, Nutt SL. Terminal differentiation of lymphocytes
depends on Blimp-1. Curr Opin Immunol. 2007 Apr;19(2):156-
62. DOI: 10.1016/j.coi.2007.01.003
108. Coker HA, Durham SR, Gould HJ. Local somatic hypermutation
and class switch recombination in the nasal mucosa of allergic
rhinitis patients. J Immunol. 2003 Nov;171(10):5602-10. DOI:
10.4049/jimmunol.171.10.5602
109. Tan BK, Li QZ, Suh L, Kato A, Conley DB, Chandra RK, Zhou J,
Norton J, Carter R, Hinchcliff M, Harris K, Peters A, Grammer LC,
Kern RC, Mohan C, Schleimer RP. Evidence for intranasal
antinuclear autoantibodies in patients with chronic rhinosinusitis
with nasal polyps. J Allergy Clin Immunol. 2011Dec;128(6):1198-
1206.e1. DOI: 10.1016/j.jaci.2011.08.037
110. Zhang N, Holtappels G, Gevaert P, Patou J, Dhaliwal B, Gould H,
Bachert C. Mucosal tissue polyclonal IgE is functional in response
to allergen and SEB. Allergy. 2011 Jan;66(1):141-8. DOI:
10.1111/j.1398-9995.2010.02448.x
111. Kowalski ML, Lewandowska-Polak A, Woźniak J, Ptasińska A,
Jankowski A, Wagrowska-Danilewicz M, Danilewicz M, Pawliczak
R. Association of stem cell factor expression in nasal polyp
epithelial cells with aspirin sensitivity and asthma. Allergy. 2005
May;60(5):631-7. DOI: 10.1111/j.1398-9995.2005.00753.x
112. Pawankar R, Lee KH, Nonaka M, Takizawa R. Role of mast cells
and basophils in chronic rhinosinusitis. Clin Allergy Immunol.
2007;20:93-101.
113. Patou J, Gevaert P, Van Zele T, Holtappels G, van Cauwenberge
P, Bachert C. Staphylococcus aureus enterotoxin B, protein A,
and lipoteichoic acid stimulations in nasal polyps. J Allergy Clin
Immunol. 2008 Jan;121(1):110-5. DOI:
10.1016/j.jaci.2007.08.059
114. Patou J, Holtappels G, Affleck K, Gevaert P, Perez-Novo C, Van
Cauwenberge P, Bachert C. Enhanced release of IgE-dependent
early phasemediators from nasal polyp tissue. J Inflamm (Lond).
2009;6:11. DOI: 10.1186/1476-9255-6-11
115. Bachert C, Gevaert P, Holtappels G, Johansson SG, van
Cauwenberge P. Total and specific IgE in nasal polyps is related
to local eosinophilic inflammation. J Allergy Clin Immunol. 2001
Apr;107(4):607-14. DOI: 10.1067/mai.2001.112374
116. Vlaminck S, Vauterin T, Hellings PW, Jorissen M, Acke F, Van
Cauwenberge P, Bachert C, Gevaert P. The importance of local
eosinophilia in the surgical outcome of chronic rhinosinusitis: a
3-year prospective observational study. Am J Rhinol Allergy. 2014
May-Jun;28(3):260-4. DOI: 10.2500/ajra.2014.28.4024
117. Meyer JE, Bartels J, Görögh T, Sticherling M, Rudack C, Ross DA,
Maune S. The role of RANTES in nasal polyposis. Am J Rhinol.
2005 Jan-Feb;19(1):15-20.
118. Bartels J, Maune S, Meyer JE, Kulke R, Schlüter C, Röwert J,
Christophers E, Schröder JM. Increased eotaxin-mRNA expression
in non-atopic and atopic nasal polyps: comparison to RANTES
and MCP-3 expression. Rhinology. 1997 Dec;35(4):171-4.
119. Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE.
Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-
2, and monocyte-chemotactic protein-4 in human airway
inflammation with eosinophilia. J Immunol. 1999
Aug;163(3):1545-51.
120. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser
K. Direct demonstration of delayed eosinophil apoptosis as a
mechanism causing tissue eosinophilia. J Immunol. 1997
Apr;158(8):3902-8.
121. Foreman A, Holtappels G, Psaltis AJ, Jervis-Bardy J, Field J,
Wormald PJ, Bachert C. Adaptive immune responses in
Staphylococcus aureus biofilm-associated chronic rhinosinusitis.
Allergy. 2011 Nov;66(11):1449-56. DOI: 10.1111/j.1398-
9995.2011.02678.x
122. Schleimer RP, Bochner BS. The effects of glucocorticoids on
human eosinophils. J Allergy Clin Immunol. 1994 Dec;94(6 Pt
2):1202-13. DOI: 10.1016/0091-6749(94)90333-6
123. Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr
S, Hens G, Hellings P, Ebbens FA, Fokkens W, Van Cauwenberge
P, Bachert C. Oral steroids and doxycycline: two different
approaches to treat nasal polyps. J Allergy Clin Immunol. 2010
May;125(5):1069-76. DOI: 10.1016/j.jaci.2010.02.020
124. Gevaert P, Bachert C, Holtappels G, Novo CP, Van der Heyden J,
Fransen L, Depraetere S, Walter H, van Cauwenberge P, Tavernier
J. Enhanced soluble interleukin-5 receptor alpha expression in
nasal polyposis. Allergy. 2003 May;58(5):371-9. DOI:
10.1034/j.1398-9995.2003.00110.x
125. Derycke L, Zhang N, Holtappels G, Dutré T, Bachert C. IL-17A as
a regulator of neutrophil survival in nasal polyp disease of
patients with and without cystic fibrosis. J Cyst Fibros. 2012
May;11(3):193-200. DOI: 10.1016/j.jcf.2011.11.007
126. Katotomichelakis M, Tantilipikorn P, Holtappels G, De Ruyck N,
Feng L, Van Zele T, Muangsomboon S, Jareonchasri P, Bunnag
C, Danielides V, Cuvelier CA, Hellings PW, Bachert C, Zhang N.
Inflammatory patterns in upper airway disease in the same
geographical area may change over time. Am J Rhinol Allergy.
2013 Sep-Oct;27(5):354-60. DOI: 10.2500/ajra.2013.27.3922
127. Serhan CN, Chiang N. Resolution phase lipid mediators of
inflammation: agonists of resolution. Curr Opin Pharmacol. 2013
Aug;13(4):632-40. DOI: 10.1016/j.coph.2013.05.012
35/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
128. Van Bruaene N, Perez-Novo C, Van Crombruggen K, De Ruyck
N, Holtappels G, Van Cauwenberge P, Gevaert P, Bachert C.
Inflammation and remodelling patterns in early stage chronic
rhinosinusitis. Clin Exp Allergy. 2012 Jun;42(6):883-90. DOI:
10.1111/j.1365-2222.2011.03898.x
129. Abreu NA, Nagalingam NA, Song Y, Roediger FC, Pletcher SD,
Goldberg AN, Lynch SV. Sinus microbiome diversity depletion
and Corynebacterium tuberculostearicum enrichment mediates
rhinosinusitis. Sci Transl Med. 2012 Sep;4(151):151ra124. DOI:
10.1126/scitranslmed.3003783
130. Ba L, Zhang N, Meng J, Zhang J, Lin P, Zhou P, Liu S, Bachert C.
The association between bacterial colonization and inflammatory
pattern in Chinese chronic rhinosinusitis patients with nasal
polyps. Allergy. 2011 Oct;66(10):1296-303. DOI:
10.1111/j.1398-9995.2011.02637.x
131. Heikkinen T, Järvinen A. The common cold. Lancet. 2003
Jan;361(9351):51-9. DOI: 10.1016/S0140-6736(03)12162-9
132. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F,
Josephs L, Symington P, O'Toole S, Myint SH, Tyrrell DA.
Community study of role of viral infections in exacerbations of
asthma in 9-11 year old children. BMJ. 1995
May;310(6989):1225-9. DOI: 10.1136/bmj.310.6989.1225
133. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and
exacerbations of asthma in adults. BMJ. 1993
Oct;307(6910):982-6. DOI: 10.1136/bmj.307.6910.982
134. Corne JM,Marshall C, Smith S, Schreiber J, Sanderson G, Holgate
ST, Johnston SL. Frequency, severity, and duration of rhinovirus
infections in asthmatic and non-asthmatic individuals: a
longitudinal cohort study. Lancet. 2002 Mar;359(9309):831-4.
DOI: 10.1016/S0140-6736(02)07953-9
135. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze
T, Contoli M, Sanderson G, Kon OM, Papi A, Jeffery PK, Stanciu
LA, Johnston SL. Rhinovirus-induced lower respiratory illness is
increased in asthma and related to virus load and Th1/2 cytokine
and IL-10 production. Proc Natl Acad Sci USA. 2008
Sep;105(36):13562-7. DOI: 10.1073/pnas.0804181105
136. Edwards MR, Regamey N, Vareille M, Kieninger E, Gupta A,
Shoemark A, Saglani S, Sykes A, Macintyre J, Davies J, Bossley
C, Bush A, Johnston SL. Impaired innate interferon induction in
severe therapy resistant atopic asthmatic children. Mucosal
Immunol. 2013 Jul;6(4):797-806. DOI: 10.1038/mi.2012.118
137. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH,
Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF,
Steinbach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ,
Sorkness CA. Randomized trial of omalizumab (anti-IgE) for
asthma in inner-city children. N Engl J Med. 2011
Mar;364(11):1005-15. DOI: 10.1056/NEJMoa1009705
138. Wang X, Zhang N, Glorieux S, Holtappels G, Vaneechoutte M,
Krysko O, Zhang L, Han D, Nauwynck HJ, Bachert C. Herpes
simplex virus type 1 infection facilitates invasion of
Staphylococcus aureus into the nasal mucosa and nasal polyp
tissue. PLoS ONE. 2012;7(6):e39875. DOI:
10.1371/journal.pone.0039875
139. Corriveau MN, Zhang N, Holtappels G, Van Roy N, Bachert C.
Detection of Staphylococcus aureus in nasal tissue with peptide
nucleic acid-fluorescence in situ hybridization. Am J Rhinol Allergy.
2009 Sep-Oct;23(5):461-5. DOI: 10.2500/ajra.2009.23.3367
140. Sachse F, Becker K, von Eiff C, Metze D, Rudack C.
Staphylococcus aureus invades the epithelium in nasal polyposis
and induces IL-6 in nasal epithelial cells in vitro. Allergy. 2010
Nov;65(11):1430-7. DOI: 10.1111/j.1398-9995.2010.02381.x
141. Van Zele T, Vaneechoutte M, Holtappels G, Gevaert P, van
Cauwenberge P, Bachert C. Detection of enterotoxin DNA in
Staphylococcus aureus strains obtained from themiddlemeatus
in controls and nasal polyp patients. Am J Rhinol. 2008 May-
Jun;22(3):223-7. DOI: 10.2500/ajr.2008.22.3161
142. Marone G, editor. Superantigens and Superallergens. Basel:
Karger; 2007.
143. Ziegler C, Goldmann O, Hobeika E, Geffers R, Peters G, Medina
E. The dynamics of T cells during persistent Staphylococcus
aureus infection: from antigen-reactivity to in vivo anergy. EMBO
Mol Med. 2011 Nov;3(11):652-66. DOI:
10.1002/emmm.201100173
144. Herz U, Rückert R, Wollenhaupt K, Tschernig T, Neuhaus-
Steinmetz U, Pabst R, Renz H. Airway exposure to bacterial
superantigen (SEB) induces lymphocyte-dependent airway
inflammation associated with increased airway responsiveness-
-a model for non-allergic asthma. Eur J Immunol. 1999
Mar;29(3):1021-31. DOI: 10.1002/(SICI)1521-
4141(199903)29:03<1021::AID-IMMU1021>3.0.CO;2-3
145. Hellings PW, Hens G, Meyts I, Bullens D, Vanoirbeek J, Gevaert
P, Jorissen M, Ceuppens JL, Bachert C. Aggravation of bronchial
eosinophilia in mice by nasal and bronchial exposure to
Staphylococcus aureus enterotoxin B. Clin Exp Allergy. 2006
Aug;36(8):1063-71. DOI: 10.1111/j.1365-2222.2006.02527.x
146. Huvenne W, Callebaut I, Plantinga M, Vanoirbeek JA, Krysko O,
Bullens DM, Gevaert P, Van Cauwenberge P, Lambrecht BN,
Ceuppens JL, Bachert C, Hellings PW. Staphylococcus aureus
enterotoxin B facilitates allergic sensitization in experimental
asthma. Clin Exp Allergy. 2010 Jul;40(7):1079-90. DOI:
10.1111/j.1365-2222.2010.03464.x
147. Huvenne W, Callebaut I, Reekmans K, Hens G, Bobic S, Jorissen
M, Bullens DM, Ceuppens JL, Bachert C, Hellings PW.
Staphylococcus aureus enterotoxin B augments granulocyte
migration and survival via airway epithelial cell activation. Allergy.
2010 Aug;65(8):1013-20. DOI: 10.1111/j.1398-
9995.2009.02313.x
148. Murakami S, Iwaki D, Mitsuzawa H, Sano H, Takahashi H, Voelker
DR, Akino T, Kuroki Y. Surfactant protein A inhibits peptidoglycan-
induced tumor necrosis factor-alpha secretion in U937 cells and
alveolar macrophages by direct interaction with toll-like receptor
2. J Biol Chem. 2002 Mar;277(9):6830-7. DOI:
10.1074/jbc.M106671200
149. Hofer MF, Lester MR, Schlievert PM, Leung DY. Upregulation of
IgE synthesis by staphylococcal toxic shock syndrome toxin-1 in
peripheral blood mononuclear cells from patients with atopic
dermatitis. Clin Exp Allergy. 1995 Dec;25(12):1218-27. DOI:
10.1111/j.1365-2222.1995.tb03046.x
150. Hofer MF, Harbeck RJ, Schlievert PM, Leung DY. Staphylococcal
toxins augment specific IgE responses by atopic patients exposed
to allergen. J Invest Dermatol. 1999 Feb;112(2):171-6. DOI:
10.1046/j.1523-1747.1999.00492.x
151. Gevaert P, Holtappels G, Johansson SG, Cuvelier C, Cauwenberge
P, Bachert C. Organization of secondary lymphoid tissue and
local IgE formation to Staphylococcus aureus enterotoxins in
nasal polyp tissue. Allergy. 2005 Jan;60(1):71-9. DOI:
10.1111/j.1398-9995.2004.00621.x
152. Bachert C, van Steen K, Zhang N, Holtappels G, Cattaert T, Maus
B, Buhl R, Taube C, Korn S, Kowalski M, Bousquet J, Howarth P.
Specific IgE against Staphylococcus aureus enterotoxins: an
independent risk factor for asthma. J Allergy Clin Immunol. 2012
Aug;130(2):376-81.e8. DOI: 10.1016/j.jaci.2012.05.012
153. Tomassen P, Jarvis D, Newson R, Van Ree R, Forsberg B, Howarth
P, Janson C, Kowalski ML, Krämer U, Matricardi PM, Middelveld
RJ, Todo-Bom A, Toskala E, Thilsing T, Brożek G, Van Drunen C,
Burney P, Bachert C. Staphylococcus aureus enterotoxin-specific
IgE is associated with asthma in the general population: a
GA(2)LEN study. Allergy. 2013 Oct;68(10):1289-97. DOI:
10.1111/all.12230
36/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
154. Song WJ, Chang YS, Lim MK, Yun EH, Kim SH, Kang HR, Park
HW, Tomassen P, Choi MH, Min KU, Cho SH, Bachert C.
Staphylococcal enterotoxin sensitization in a community-based
population: a potential role in adult-onset asthma. Clin Exp
Allergy. 2014 Apr;44(4):553-62. DOI: 10.1111/cea.12239
155. Semic-Jusufagic A, Bachert C, Gevaert P, Holtappels G, Lowe L,
Woodcock A, Simpson A, Custovic A. Staphylococcus aureus
sensitization and allergic disease in early childhood: population-
based birth cohort study. J Allergy Clin Immunol. 2007
Apr;119(4):930-6. DOI: 10.1016/j.jaci.2006.12.639
156. Hollams EM, Hales BJ, Bachert C, Huvenne W, Parsons F, de
Klerk NH, Serralha M, Holt BJ, Ahlstedt S, Thomas WR, Sly PD,
Holt PG. Th2-associated immunity to bacteria in teenagers and
susceptibility to asthma. Eur Respir J. 2010 Sep;36(3):509-16.
DOI: 10.1183/09031936.00184109
157. Schubert MS. Allergic fungal sinusitis. Clin Rev Allergy Immunol.
2006 Jun;30(3):205-16. DOI: 10.1385/CRIAI:30:3:205
158. Schubert MS. Allergic fungal sinusitis: pathophysiology, diagnosis
and management. Med Mycol. 2009;47 Suppl 1:S324-30. DOI:
10.1080/13693780802314809
159. Dutre T, Al Dousary S, Zhang N, Bachert C. Allergic fungal
rhinosinusitis-more than a fungal disease? J Allergy Clin Immunol.
2013 Aug;132(2):487-9.e1. DOI: 10.1016/j.jaci.2013.02.040
160. Scadding GK, Durham SR, Mirakian R, Jones NS, Drake-Lee AB,
Ryan D, Dixon TA, Huber PA, Nasser SM; British Society for Allergy
and Clinical Immunology. BSACI guidelines for the management
of rhinosinusitis and nasal polyposis. Clin Exp Allergy. 2008
Feb;38(2):260-75. DOI: 10.1111/j.1365-2222.2007.02889.x
161. Accomazzo MR, Rovati GE, Viganò T, Hernandez A, Bonazzi A,
Bolla M, Fumagalli F, Viappiani S, Galbiati E, Ravasi S, Albertoni
C, Di Luca M, Caputi A, Zannini P, Chiesa G, Villa AM, Doglia SM,
Folco G, Nicosia S. Leukotriene D4-induced activation of smooth-
muscle cells from human bronchi is partly Ca2+-independent.
Am J Respir Crit Care Med. 2001 Jan;163(1):266-72. DOI:
10.1164/ajrccm.163.1.9912019
162. Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl
leukotrienes. Prostaglandins Leukot Essent Fatty Acids. 2003
Aug-Sep;69(2-3):135-43. DOI: 10.1016/S0952-3278(03)00074-
7
163. Roca-Ferrer J, Garcia-Garcia FJ, Pereda J, Perez-Gonzalez M,
Pujols L, Alobid I, Mullol J, Picado C. Reduced expression of COXs
and production of prostaglandin E(2) in patients with nasal polyps
with or without aspirin-intolerant asthma. J Allergy Clin Immunol.
2011 Jul;128(1):66-72.e1. DOI: 10.1016/j.jaci.2011.01.065
164. Pérez-Novo CA, Claeys C, Van Cauwenberge P, Bachert C.
Expression of eicosanoid receptors subtypes and eosinophilic
inflammation: implication on chronic rhinosinusitis. Respir Res.
2006;7:75. DOI: 10.1186/1465-9921-7-75
165. Liu CM, Hong CY, Shun CT, Hsiao TY, Wang CC, Wang JS, Hsiao
M, Lin SK. Inducible cyclooxygenase and interleukin 6 gene
expressions in nasal polyp fibroblasts: possible implication in
the pathogenesis of nasal polyposis. Arch Otolaryngol Head Neck
Surg. 2002 Aug;128(8):945-51. DOI:
10.1001/archotol.128.8.945
166. Okano M, Fujiwara T, Yamamoto M, Sugata Y, Matsumoto R,
Fukushima K, Yoshino T, Shimizu K, Eguchi N, Kiniwa M, Urade
Y, Nishizaki K. Role of prostaglandin D2 and E2 terminal
synthases in chronic rhinosinusitis. Clin Exp Allergy. 2006
Aug;36(8):1028-38. DOI: 10.1111/j.1365-2222.2006.02528.x
167. YamamotoM, OkanoM, Fujiwara T, Kariya S, Higaki T, Nagatsuka
H, Tsujigiwa H, Yamada M, Yoshino T, Urade Y, Nishizaki K.
Expression and characterization of PGD2 receptors in chronic
rhinosinusitis: modulation of DP and CRTH2 by PGD2. Int Arch
Allergy Immunol. 2009;148(2):127-36. DOI:
10.1159/000155743
168. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L,
Serhan CN, Szczeklik A. Aspirin-tolerant asthmatics generate
more lipoxins than aspirin-intolerant asthmatics. Eur Respir J.
2000 Jul;16(1):44-9. DOI: 10.1034/j.1399-3003.2000.16a08.x
169. Videler WJ, Badia L, Harvey RJ, Gane S, Georgalas C, van der
Meulen FW, Menger DJ, Lehtonen MT, Toppila-Salmi SK, Vento
SI, Hytönen M, Hellings PW, Kalogjera L, Lund VJ, Scadding G,
Mullol J, Fokkens WJ. Lack of efficacy of long-term, low-dose
azithromycin in chronic rhinosinusitis: a randomized controlled
trial. Allergy. 2011 Nov;66(11):1457-68. DOI: 10.1111/j.1398-
9995.2011.02693.x
170. Cervin A, Wallwork B. Efficacy and safety of long-term antibiotics
(macrolides) for the treatment of chronic rhinosinusitis. Curr
Allergy Asthma Rep. 2014 Mar;14(3):416. DOI:
10.1007/s11882-013-0416-2
171. Coles CL, Mabula K, Seidman JC, Levens J, Mkocha H, Munoz
B, Mfinanga SG, West S. Mass distribution of azithromycin for
trachoma control is associated with increased risk of
azithromycin-resistant Streptococcus pneumoniae carriage in
young children 6 months after treatment. Clin Infect Dis. 2013
Jun;56(11):1519-26. DOI: 10.1093/cid/cit137
172. Schafer T, Schnoor M, Wagenmann M, Klimek L, Bachert C.
Therapeutic Index (TIX) for intranasal corticosteroids in the
treatment of allergic rhinitis. Rhinology. 2011 Aug;49(3):272-80.
DOI: 10.4193/Rhino10.170
173. Pérez-Novo CA, Kowalski ML, Kuna P, Ptasinska A, Holtappels
G, van Cauwenberge P, Gevaert P, Johannson S, Bachert C.
Aspirin sensitivity and IgE antibodies to Staphylococcus aureus
enterotoxins in nasal polyposis: studies on the relationship. Int
Arch Allergy Immunol. 2004 Mar;133(3):255-60. DOI:
10.1159/000076832
174. Klimek L, Dollner R, Pfaar O, Mullol J. Aspirin desensitization:
useful treatment for chronic rhinosinusitis with nasal polyps
(CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?
Curr Allergy Asthma Rep. 2014 Jun;14(6):441. DOI:
10.1007/s11882-014-0441-9
175. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M,
McAlary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Della
Cioppa G; Omalizumab Seasonal Allergic Rhinitis Trail Group.
Effect of omalizumab on symptoms of seasonal allergic rhinitis:
a randomized controlled trial. JAMA. 2001 Dec;286(23):2956-
67. DOI: 10.1001/jama.286.23.2956
176. Donovan R, Johansson SG, Bennich H, Soothill JF.
Immunoglobulins in nasal polyp fluid. Int Arch Allergy Appl
Immunol. 1970;37(2):154-66. DOI: 10.1159/000230229
177. Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the
treatment of allergic rhinitis--and eventually nasal polyps? Int
Arch Allergy Immunol. 2009;148(2):87-98. DOI:
10.1159/000155739
178. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio
RM. A randomized, double-blind, placebo-controlled trial of anti-
IgE for chronic rhinosinusitis. Rhinology. 2010 Sep;48(3):318-
24. DOI: 10.4193/Rhin09.144
179. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C.
The anti-inflammatory effects of omalizumab confirm the central
role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005
Mar;115(3):459-65. DOI: 10.1016/j.jaci.2004.11.053
180. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters
W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P,
Bachert C. Omalizumab is effective in allergic and nonallergic
patients with nasal polyps and asthma. J Allergy Clin Immunol.
2013 Jan;131(1):110-6.e1. DOI: 10.1016/j.jaci.2012.07.047
37/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
181. Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé
C, Devouassoux G, de Blay F, Couderc LJ, Didier A, O'Callaghan
DS, Girodet PO, Bourdeix I, Le Gros V, Humbert M. A proof-of-
concept, randomized, controlled trial of omalizumab in patients
with severe, difficult-to-control, nonatopic asthma. Chest. 2013
Aug;144(2):411-9. DOI: 10.1378/chest.12-1961
182. Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen
M. Efficacy of omalizumab in the treatment of nasal polyps.
Thorax. 2011 Sep;66(9):824-5. DOI: 10.1136/thx.2010.152835
183. Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley
MS, Iribarren C, Chen H, Carrigan G, Rosén K, Szefler SJ.
Incidence of malignancy in patients with moderate-to-severe
asthma treated with or without omalizumab. J Allergy Clin
Immunol. 2014 Sep;134(3):560-7. DOI:
10.1016/j.jaci.2014.02.007
184. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger
H, Van Zele T, Holtappels G, Tavernier J, van Cauwenberge P,
Bachert C. Nasal IL-5 levels determine the response to anti-IL-5
treatment in patients with nasal polyps. J Allergy Clin Immunol.
2006 Nov;118(5):1133-41. DOI: 10.1016/j.jaci.2006.05.031
185. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda
F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE,
Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G.
Dupilumab in persistent asthma with elevated eosinophil levels.
N Engl J Med. 2013 Jun;368(26):2455-66. DOI:
10.1056/NEJMoa1304048
186. Bermúdez-Humarán LG, Aubry C, Motta JP, Deraison C, Steidler
L, Vergnolle N, Chatel JM, Langella P. Engineering lactococci and
lactobacilli for human health. Curr Opin Microbiol. 2013
Jun;16(3):278-83. DOI: 10.1016/j.mib.2013.06.002
187. Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM,
Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel
J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T,
Buhl R, Renz J, Garn H, Renz H. Allergen-induced asthmatic
responsesmodified by a GATA3-specific DNAzyme. N Engl J Med.
2015 May;372(21):1987-95. DOI: 10.1056/NEJMoa1411776
188. Kerkhoff C, Sorg C, Tandon NN, Nacken W. Interaction of
S100A8/S100A9-arachidonic acid complexes with the scavenger
receptor CD36 may facilitate fatty acid uptake by endothelial
cells. Biochemistry. 2001 Jan;40(1):241-8. DOI:
10.1021/bi001791k
189. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ,
Hashemi M, Wesselborg S, Kerkhoff C, Los M. S100A8/A9 at
low concentration promotes tumor cell growth via RAGE ligation
and MAP kinase-dependent pathway. J Leukoc Biol. 2008
Jun;83(6):1484-92. DOI: 10.1189/jlb.0607397
190. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and
S100A9 mediate endotoxin-induced cardiomyocyte dysfunction
via the receptor for advanced glycation end products. Circ Res.
2008 May;102(10):1239-46. DOI:
10.1161/CIRCRESAHA.107.167544
191. Bryborn M, Adner M, Cardell LO. Psoriasin, one of several new
proteins identified in nasal lavage fluid from allergic and non-
allergic individuals using 2-dimensional gel electrophoresis and
mass spectrometry. Respir Res. 2005;6:118. DOI:
10.1186/1465-9921-6-118
192. Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100
proteins to RAGE: an update. Biochim Biophys Acta. 2009
Jun;1793(6):993-1007. DOI: 10.1016/j.bbamcr.2008.11.016
193. Fritz G. RAGE: a single receptor fits multiple ligands. Trends
Biochem Sci. 2011 Dec;36(12):625-32. DOI:
10.1016/j.tibs.2011.08.008
194. Lee HM, Kang HJ, Woo JS, Chae SW, Lee SH, Hwang SJ.
Upregulation of surfactant protein A in chronic rhinosinusitis.
Laryngoscope. 2006 Feb;116(2):328-30. DOI:
10.1097/01.mlg.0000194223.22763.5f
195. Wang X, Zhao C, Liu M. Expression and significance of surfactant
A in nasal polyps of chronic rhinosinusitis. Lin Chung Er Bi Yan
Hou Tou Jing Wai Ke Za Zhi. 2010 Jul;24(14):652-4.
196. Woodworth BA, Wood R, Baatz JE, Schlosser RJ. Sinonasal
surfactant protein A1, A2, and D gene expression in cystic
fibrosis: a preliminary report. Otolaryngol Head Neck Surg. 2007
Jul;137(1):34-8. DOI: 10.1016/j.otohns.2007.01.025
197. Skinner ML, Schlosser RJ, Lathers D, Neal JG, Woodworth BA,
Hall J, Newton DA, Baatz JE. Innate and adaptive mediators in
cystic fibrosis and allergic fungal rhinosinusitis. Am J Rhinol.
2007 Sep-Oct;21(5):538-41. DOI: 10.2500/ajr.2007.21.3070
198. Ooi EH, Wormald PJ, Carney AS, James CL, Tan LW. Surfactant
protein d expression in chronic rhinosinusitis patients and
immune responses in vitro to Aspergillus and alternaria in a nasal
explant model. Laryngoscope. 2007 Jan;117(1):51-7. DOI:
10.1097/01.mlg.0000243196.75418.6f
199. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M,
Si-Tahar M. Cutting edge: the immunostimulatory activity of the
lung surfactant protein-A involves Toll-like receptor 4. J Immunol.
2002 Jun;168(12):5989-92. DOI:
10.4049/jimmunol.168.12.5989
200. Henning LN, Azad AK, Parsa KV, Crowther JE, Tridandapani S,
Schlesinger LS. Pulmonary surfactant protein A regulates TLR
expression and activity in humanmacrophages. J Immunol. 2008
Jun;180(12):7847-58. DOI: 10.4049/jimmunol.180.12.7847
201. Ohya M, Nishitani C, Sano H, Yamada C, Mitsuzawa H, Shimizu
T, Saito T, Smith K, Crouch E, Kuroki Y. Human pulmonary
surfactant protein D binds the extracellular domains of Toll-like
receptors 2 and 4 through the carbohydrate recognition domain
by amechanism different from its binding to phosphatidylinositol
and lipopolysaccharide. Biochemistry. 2006 Jul;45(28):8657-
64. DOI: 10.1021/bi060176z
202. Yamada C, Sano H, Shimizu T, Mitsuzawa H, Nishitani C, Himi T,
Kuroki Y. Surfactant protein A directly interacts with TLR4 and
MD-2 and regulates inflammatory cellular response. Importance
of supratrimeric oligomerization. J Biol Chem. 2006
Aug;281(31):21771-80. DOI: 10.1074/jbc.M513041200
203. Kalfa VC, Spector SL, Ganz T, Cole AM. Lysozyme levels in the
nasal secretions of patients with perennial allergic rhinitis and
recurrent sinusitis. Ann Allergy Asthma Immunol. 2004
Sep;93(3):288-92. DOI: 10.1016/S1081-1206(10)61503-7
204. Bascom R, Pipkorn U, Proud D, Dunnette S, Gleich GJ,
Lichtenstein LM, Naclerio RM.Major basic protein and eosinophil-
derived neurotoxin concentrations in nasal-lavage fluid after
antigen challenge: effect of systemic corticosteroids and
relationship to eosinophil influx. J Allergy Clin Immunol. 1989
Sep;84(3):338-46. DOI: 10.1016/0091-6749(89)90418-1
205. Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR,Michalek
SM, Rosenberg HF, Zhang N, Oppenheim JJ. Eosinophil-derived
neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal
pathway in dendritic cells and enhances Th2 immune responses.
J Exp Med. 2008 Jan;205(1):79-90. DOI:
10.1084/jem.20062027
206. Bilodeau L, Boulay ME, Prince P, Boisvert P, Boulet LP.
Comparative clinical and airway inflammatory features of
asthmatics with or without polyps. Rhinology. 2010
Dec;48(4):420-5. DOI: 10.4193/Rhino09.095
207. Nakagawa T, Yamane H, Shigeta T, Takashima T, Nakai Y.
Interaction between fibronectin and eosinophils in the growth of
nasal polyps. Laryngoscope. 1999 Apr;109(4):557-61. DOI:
10.1097/00005537-199904000-00007
208. Sobol SE, Christodoulopoulos P, Manoukian JJ, Hauber HP,
Frenkiel S, Desrosiers M, Fukakusa M, Schloss MD, Hamid Q.
Cytokine profile of chronic sinusitis in patients with cystic fibrosis.
Arch Otolaryngol Head Neck Surg. 2002 Nov;128(11):1295-8.
DOI: 10.1001/archotol.128.11.1295
38/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
209. Bachert C, Zhang N. Chronic rhinosinusitis and asthma: novel
understanding of the role of IgE 'above atopy'. J InternMed. 2012
Aug;272(2):133-43. DOI: 10.1111/j.1365-2796.2012.02559.x
210. Liu Y, Zhang S, Li DW, Jiang SJ. Efficacy of anti-interleukin-5
therapy with mepolizumab in patients with asthma: a meta-
analysis of randomized placebo-controlled trials. PLoS ONE.
2013;8(3):e59872. DOI: 10.1371/journal.pone.0059872
211. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J,
Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group.
Reslizumab for poorly controlled, eosinophilic asthma: a
randomized, placebo-controlled study. Am J Respir Crit CareMed.
2011 Nov;184(10):1125-32. DOI: 10.1164/rccm.201103-
0396OC
212. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R,
Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino
NA. Effects of benralizumab on airway eosinophils in asthmatic
patients with sputum eosinophilia. J Allergy Clin Immunol. 2013
Nov;132(5):1086-1096.e5. DOI: 10.1016/j.jaci.2013.05.020
213. ClinicalTrialsRegister.eu [Internet]. London: EuropeanMedicines
Agency; c1995-2015. Available from: https://
www.clinicaltrialsregister.eu
214. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the
treatment of asthma. Nat Rev Drug Discov. 2012
Dec;11(12):958-72. DOI: 10.1038/nrd3792
215. Steinke JW. Anti-interleukin-4 therapy. Immunol Allergy Clin North
Am. 2004 Nov;24(4):599-614, vi. DOI:
10.1016/j.iac.2004.06.008
216. Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel
SE, Meyers DA, Bleecker ER. IL-4 receptor polymorphisms predict
reduction in asthma exacerbations during response to an anti-
IL-4 receptor alpha antagonist. J Allergy Clin Immunol. 2012
Aug;130(2):516-22.e4. DOI: 10.1016/j.jaci.2012.03.030
217. Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA. A
randomized, controlled trial to evaluate the effect of an anti-
interleukin-9 monoclonal antibody in adults with uncontrolled
asthma. Respir Res. 2013;14:93. DOI: 10.1186/1465-9921-
14-93
218. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin SL.
Randomized, double-blind, placebo-controlled study of
brodalumab, a human anti-IL-17 receptor monoclonal antibody,
in moderate to severe asthma. Am J Respir Crit Care Med. 2013
Dec;188(11):1294-302. DOI: 10.1164/rccm.201212-2318OC
219. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D,
Kell C, May RD, Geba GP, Molfino NA. A phase II placebo-
controlled study of tralokinumab in moderate-to-severe asthma.
Eur Respir J. 2013 Feb;41(2):330-8. DOI:
10.1183/09031936.00223411
220. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten
C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L,
Kasaian MT, Killian KJ, Strinich TX, Watson RM, Y N, Zhou S,
Raible D, O'Byrne PM. Effects of interleukin-13 blockade on
allergen-induced airway responses in mild atopic asthma. Am J
Respir Crit Care Med. 2011 Apr;183(8):1007-14. DOI:
10.1164/rccm.201008-1210OC
221. Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR,
Zheng Y, PutnamWS, Parsey MV, Bohen SP, Matthews JG. Dose-
ranging study of lebrikizumab in asthmatic patients not receiving
inhaled steroids. J Allergy Clin Immunol. 2013 Sep;132(3):567-
74. DOI: 10.1016/j.jaci.2013.03.051
222. Scheerens H, Arron JR, Zheng Y, PutnamWS, Erickson RW, Choy
DF, Harris JM, Lee J, Jarjour NN, Matthews JG. The effects of
lebrikizumab in patients with mild asthma following whole lung
allergen challenge. Clin Exp Allergy. 2014 Jan;44(1):38-46. DOI:
10.1111/cea.12220
223. Barnes PJ. New therapies for asthma: is there any progress?
Trends Pharmacol Sci. 2010 Jul;31(7):335-43. DOI:
10.1016/j.tips.2010.04.009
224. Taillé C, Poulet C, Marchand-Adam S, Borie R, Dombret MC,
Crestani B, Aubier M. Monoclonal Anti-TNF-α Antibodies for
Severe Steroid-Dependent Asthma: A Case Series. Open Respir
Med J. 2013;7:21-5. DOI: 10.2174/1874306401307010021
225. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler
J, FitzGerald JM, Boedigheimer M, Davis BE, Dias C, Gorski KS,
Smith L, Bautista E, Comeau MR, Leigh R, Parnes JR. Effects of
an anti-TSLP antibody on allergen-induced asthmatic responses.
N Engl J Med. 2014 May;370(22):2102-10. DOI:
10.1056/NEJMoa1402895
226. Neighbour H, Boulet LP, Lemiere C, Sehmi R, Leigh R, Sousa AR,
Martin J, Dallow N, Gilbert J, Allen A, Hall D, Nair P. Safety and
efficacy of an oral CCR3 antagonist in patients with asthma and
eosinophilic bronchitis: a randomized, placebo-controlled clinical
trial. Clin Exp Allergy. 2014 Apr;44(4):508-16. DOI:
10.1111/cea.12244
227. Busse WW, Wenzel SE, Meltzer EO, Kerwin EM, Liu MC, Zhang
N, Chon Y, Budelsky AL, Lin J, Lin SL. Safety and efficacy of the
prostaglandin D2 receptor antagonist AMG 853 in asthmatic
patients. J Allergy Clin Immunol. 2013 Feb;131(2):339-45. DOI:
10.1016/j.jaci.2012.10.013
228. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM,
Stryszak P, Gann L, Sadeh J, Chanez P; Study Investigators. Safety
and efficacy of a CXCR2 antagonist in patients with severe
asthma and sputum neutrophils: a randomized, placebo-
controlled clinical trial. Clin Exp Allergy. 2012 Jul;42(7):1097-
103. DOI: 10.1111/j.1365-2222.2012.04014.x
229. Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-
Haenni A, Willers J, Stocker H, Mueller P, Bachmann MF, Renner
WA. The novel TLR-9 agonist QbG10 shows clinical efficacy in
persistent allergic asthma. J Allergy Clin Immunol. 2013
Mar;131(3):866-74. DOI: 10.1016/j.jaci.2012.12.1561
230. ClinicalTrials.gov [Internet]. Bethesda, Maryland: NIH; c1993-
[updated May 2014]. Available from: https://clinicaltrials.gov/
231. Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N,
Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M,
Calzetta L, Singh D, Spina D, Walker MJ, Page CP. Efficacy and
safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy
volunteers and in patients with asthma or chronic obstructive
pulmonary disease: findings from four clinical trials. Lancet Respir
Med. 2013 Nov;1(9):714-27. DOI: 10.1016/S2213-
2600(13)70187-5
232. Sel S, Wegmann M, Dicke T, Sel S, Henke W, Yildirim AO, Renz
H, Garn H. Effective prevention and therapy of experimental
allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin
Immunol. 2008 Apr;121(4):910-6. DOI:
10.1016/j.jaci.2007.12.1175
Corresponding author:
Dr. Dr. h. c. Claus Bachert, MD, PhD
Department of Otolaryngology and Upper Airways
Research Laboratory, Ghent University, De Pintelaan 185,
9000 Ghent, Belgium
Claus.Bachert@ugent.be
Please cite as
Bachert C, Holtappels G. Pathophysiology of chronic rhinosinusitis,
pharmaceutical therapy options. GMS Curr Top Otorhinolaryngol Head
Neck Surg. 2015;14:Doc09.
DOI: 10.3205/cto000124, URN: urn:nbn:de:0183-cto0001242
39/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
This article is freely available from
http://www.egms.de/en/journals/cto/2015-14/cto000124.shtml
Published: 2015-09-30
Copyright
©2015 Bachert et al. This is an Open Access article distributed under
the terms of the Creative Commons Attribution 4.0 License. See license
information at http://creativecommons.org/licenses/by/4.0/.
40/40GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2015, Vol. 14, ISSN 1865-1011
Bachert et al.: Pathophysiology of chronic rhinosinusitis, pharmaceutical ...
